67 results on '"de Francesco, D."'
Search Results
2. 1712P Safety and efficacy of influenza and pneumococcal vaccines in cancer patients on active therapy: A prospective study
- Author
-
La Verde, N.M., primary, Dalu, D., additional, Ridolfo, A.L., additional, Cona, M.S., additional, De Francesco, D., additional, Riva, A., additional, Antinori, S., additional, Rota, S., additional, Tricella, C., additional, Oldani, S., additional, Fasola, C., additional, Ferrario, S., additional, Gambaro, A., additional, Filipazzi, V., additional, Chizzoniti, D., additional, Cattaneo, M., additional, Di Carlo, F., additional, Stocchetti, B. Lombardi, additional, Tosca, N., additional, and Galli, M., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
- Author
-
De Francesco, Davide, Wit, Ferdinand W., Burkle, Alexander, Oehlke, Sebastian, Kootstra, Neeltje A., Winston, Alan, Franceschi, Claudio, Garagnani, Paolo, Pirazzini, Chiara, Libert, Claude, Grune, Tilman, Weber, Daniela, Jansen, Eugene H. J. M., Sabin, Caroline A., Reiss, Peter, Reiss, P., Winston, A., Wit, F. W., Prins, M., van der Loeff, M. F. Schim, Schouten, J., Schmand, B., Geurtsen, G. J., Sharp, D. J., Caan, M. W. A., Majoie, C., Villaudy, J., Berkhout, B., Kootstra, N. A., Gisslen, M., Pasternak, A., Sabin, C. A., Guaraldi, G., Burkle, A., Libert, C., Franceschi, C., Kalsbeek, A., Fliers, E., Hoeijmakers, J., Pothof, J., van der Valk, M., Bisschop, P. H., Portegies, P., Zaheri, S., Burger, D., Cole, J. H., Biirkle, A., Zikkenheiner, W., Janssen, F. R., Underwood, J., Kooij, K. W., van Zoest, R. A., Doyle, N., van der Loeff, M. Schim, Schmand, B. A., Verheij, E., Verboeket, S. O., Elsenga, B. C., Hillebregt, M. M. J., Ruijs, Y. M. C., Benschop, D. P., Tembo, L., McDonald, L., Stott, M., Legg, K., Lovell, A., Erlwein, O., Kingsley, C., Norsworthy, P., Mullaney, S., Kruijer, T., del Grande, L., Olthof, V, Visser, G. R., May, L., Verbraak, F., Demirkaya, N., Visser, I, Majoie, C. B. L. M., Su, T., Leech, R., Huguet, J., Frankin, E., van der Kuyl, A., Weijer, K., Siteur-Van Rijnstra, E., Harskamp-Holwerda, A. M., Maurer, I, Ruiz, M. M. Mangas, Girigorie, A. F., Boeser-Nunnink, B., Kals-Beek, A., Bisschop, P. H. L. T., de Graaff-Teulen, M., Dewaele, S., Garagnani, P., Pirazzini, C., Capri, M., Dall'Olio, F., Chiricolo, M., Salvioli, S., Fuchs, D., Zetterberg, H., Weber, D., Grune, T., Jansen, E. H. J. M., De Francesco, D., Sindlinger, T., Oehlke, S., Global Health, AII - Infectious diseases, APH - Aging & Later Life, Experimental Immunology, ANS - Neurodegeneration, AMS - Restoration & Development, Medical Psychology, and APH - Mental Health
- Subjects
Male ,0301 basic medicine ,CYTOMEGALOVIRUS ,HIV Infections ,DISEASE ,0302 clinical medicine ,Biomarkers of aging ,Medicine and Health Sciences ,Immunology and Allergy ,030212 general & internal medicine ,the Co-morBidity in Relation to AIDS (COBRA) Collaboration ,POPULATION ,Immunodeficiency ,education.field_of_study ,premature aging ,virus diseases ,11 Medical And Health Sciences ,Middle Aged ,Hepatitis B ,SOUTH-AFRICA ,Infectious Diseases ,Anti-Retroviral Agents ,Cohort ,Female ,Life Sciences & Biomedicine ,medicine.drug ,Adult ,Premature aging ,medicine.medical_specialty ,BIOMARKERS ,Immunology ,Population ,biomarkers of aging ,17 Psychology And Cognitive Sciences ,03 medical and health sciences ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,ddc:570 ,Internal medicine ,medicine ,Humans ,accelerated aging ,education ,Aged ,accelerated aging, aging, biological age, biomarkers of aging, HIV, premature aging ,Science & Technology ,business.industry ,aging ,Biology and Life Sciences ,HIV ,06 Biological Sciences ,medicine.disease ,COMORBIDITIES ,biological age ,INFECTED INDIVIDUALS ,IMMUNOGLOBULIN-G ANTIBODY ,PROTEASE INHIBITORS ,Cross-Sectional Studies ,030104 developmental biology ,RISK-FACTORS ,business ,Saquinavir - Abstract
Objectives: Despite successful antiretroviral (ARV) therapy, people living with HIV (PLWH) may show signs of premature/accentuated aging. We compared established biomarkers of aging in PLWH, appropriately-chosen HIV-negative individuals, and blood donors, and explored factors associated with biological age advancement.Design: Cross-sectional analysis of 134 PLWH on suppressive ARV therapy, 79 lifestyle-comparable HIV-negative controls aged ≥45 years from the Co-morBidity in Relation to AIDS (COBRA) cohort, and 35 age-matched blood donors (BD).Methods: Biological age was estimated using a validated algorithm based on ten biomarkers. Associations between ‘age advancement’ (biological minus chronological age) and HIV status/parameters, lifestyle, cytomegalovirus (CMV), hepatitis B (HBV) and hepatitis C virus (HCV) infections were investigated using linear regression.Results: The average (95% CI) age advancement was greater in both HIV-positive [13.2 (11.6, 14.9) years] and HIV-negative [5.5 (3.8, 7.2) years] COBRA participants compared to BD [-7.0 (-4.1, -9.9) years, both p's < 0.001)], but also in HIV-positive compared to HIV-negative participants (p < 0.001). Chronic HBV, higher anti-CMV IgG titer and CD8+ T-cell count were each associated with increased age advancement, independently of HIV-status/group. Among HIV-positive participants, age advancement was increased by 3.5 (0.1, 6.8) years among those with nadir CD4+ < 200 cells/μL and by 0.1 (0.06, 0.2) years for each additional month of exposure to saquinavir.Conclusions: Both treated PLWH and lifestyle-comparable HIV-negative individuals show signs of age advancement compared to BD, to which persistent CMV, HBV co-infection and CD8+ T-cell activation may have contributed. Age advancement remained greatest in PLWH and was related to prior immunodeficiency and cumulative saquinavir exposure. published
- Published
- 2019
4. Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment
- Author
-
Underwood, Jonathan, De Francesco, Davide, Cole, James H, Caan, Matthan W A, van Zoest, Rosan A, Schmand, Ben A, Sharp, David J, Sabin, Caroline A, Reiss, Peter, Winston, Alan Coolaboratori: Reiss P, Wit FWNM, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Janssen FR, Heidenrijk M, Zikkenheiner W, van der Valk M, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Mangas Ruiz MM, Girigorie AF, Villaudy J, Frankin E, Pasternak A, Berkhout B, van der Kuyl T, Portegies P, Schmand BA, Geurtsen GJ, Ter Stege JA, Klein Twennaar M, Majoie CBLM, Caan MWA, Su T, Weijer K, Bisschop PHLT, Kalsbeek A, Wezel M, Visser I, Ruhé HG, Franceschi C, Garagnani P, Pirazzini C, Capri M, Dall'Olio F, Chiricolo M, Salvioli S, Hoeijmakers J, Pothof J, Prins M, Martens M, Moll S, Berkel J, Totté M, Kovalev S, Gisslén M, Fuchs D, Zetterberg H, Winston A, Underwood J, McDonald L, Stott M, Legg K, Lovell A, Erlwein O, Doyle N, Kingsley C, Sharp DJ, Leech R, Cole JH, Zaheri S, Hillebregt MMJ, Ruijs YMC, Benschop DP, Burger D, de Graaff-Teulen M, Guaraldi G, Bürkle A, Sindlinger T, Moreno-Villanueva M, Keller A, Sabin C, de Francesco D, Libert C, Dewaele S, Boffito M, Mallon P, Post F, Sachikonye M, Anderson J, Asboe D, Garvey L, Pozniak A, Vera J, Williams I, Campbell L, Yurdakul S, Okumu S, Pollard L, Otiko D, Phillips L, Laverick R, Fisher M, Clarke A, Bexley A, Richardson C, Macken A, Ghavani-Kia B, Maher J, Byrne M, Flaherty A, Mguni S, Clark R, Nevin-Dolan R, Pelluri S, Johnson M, Ngwu N, Hemat N, Jones M, Carroll A, Whitehouse A, Burgess L, Babalis D, Higgs C, Seah E, Fletcher S, Anthonipillai M, Moyes A, Deats K, Syed I, Matthews C., Underwood, Jonathan, De Francesco, Davide, Cole, James H, Caan, Matthan W A, van Zoest, Rosan A, Schmand, Ben A, Sharp, David J, Sabin, Caroline A, Reiss, Peter, Winston, Alan Coolaboratori: Reiss P, Wit FWNM, Schouten J, Kooij KW, van Zoest RA, Elsenga BC, Janssen FR, Heidenrijk M, Zikkenheiner W, van der Valk M, Kootstra NA, Harskamp-Holwerda AM, Maurer I, Mangas Ruiz MM, Girigorie AF, Villaudy J, Frankin E, Pasternak A, Berkhout B, van der Kuyl T, Portegies P, Schmand BA, Geurtsen GJ, Ter Stege JA, Klein Twennaar M, Majoie CBLM, Caan MWA, Su T, Weijer K, Bisschop PHLT, Kalsbeek A, Wezel M, Visser I, Ruhé HG, Franceschi C, Garagnani P, Pirazzini C, Capri M, Dall'Olio F, Chiricolo M, Salvioli S, Hoeijmakers J, Pothof J, Prins M, Martens M, Moll S, Berkel J, Totté M, Kovalev S, Gisslén M, Fuchs D, Zetterberg H, Winston A, Underwood J, McDonald L, Stott M, Legg K, Lovell A, Erlwein O, Doyle N, Kingsley C, Sharp DJ, Leech R, Cole JH, Zaheri S, Hillebregt MMJ, Ruijs YMC, Benschop DP, Burger D, de Graaff-Teulen M, Guaraldi G, Bürkle A, Sindlinger T, Moreno-Villanueva M, Keller A, Sabin C, de Francesco D, Libert C, Dewaele S, Boffito M, Mallon P, Post F, Sabin C, Sachikonye M, Winston A, Anderson J, Asboe D, Boffito M, Garvey L, Mallon P, Post F, Pozniak A, Sabin C, Sachikonye M, Vera J, Williams I, Winston A, Post F, Campbell L, Yurdakul S, Okumu S, Pollard L, Williams I, Otiko D, Phillips L, Laverick R, Fisher M, Clarke A, Vera J, Bexley A, Richardson C, Mallon P, Macken A, Ghavani-Kia B, Maher J, Byrne M, Flaherty A, Anderson J, Mguni S, Clark R, Nevin-Dolan R, Pelluri S, Johnson M, Ngwu N, Hemat N, Jones M, Carroll A, Whitehouse A, Burgess L, Babalis D, Winston A, Garvey L, Underwood J, Stott M, McDonald L, Boffito M, Asboe D, Pozniak A, Higgs C, Seah E, Fletcher S, Anthonipillai M, Moyes A, Deats K, Syed I, Matthews C., Molecular Genetics, Biomedical Engineering and Physics, Radiology and Nuclear Medicine, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, ACS - Microcirculation, AMS - Restoration & Development, Amsterdam Neuroscience - Brain Imaging, Amsterdam Neuroscience - Neurovascular Disorders, Graduate School, AII - Infectious diseases, APH - Aging & Later Life, Medical Psychology, Amsterdam Neuroscience - Neurodegeneration, Global Health, Infectious diseases, APH - Mental Health, APH - Methodology, Commission of the European Communities, Imperial College Healthcare NHS Trust- BRC Funding, and National Institute for Health Research
- Subjects
Multivariate statistics ,medicine.medical_specialty ,COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group ,Immunology ,Human immunodeficiency virus (HIV) ,Audiology ,medicine.disease_cause ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,multivariate ,SDG 3 - Good Health and Well-being ,Neuroimaging ,Medicine and Health Sciences ,medicine ,Major Article ,OLDER-PEOPLE ,030212 general & internal medicine ,VALIDITY ,Cognitive impairment ,cognitive impairment ,Science & Technology ,neuroimaging ,SCORES ,business.industry ,Biology and Life Sciences ,HIV ,MEN ,Cognition ,Mental health ,White matter microstructure ,PREVALENCE ,3. Good health ,Infectious Diseases ,Oncology ,REGISTRATION ,business ,Life Sciences & Biomedicine ,Neurocognitive ,030217 neurology & neurosurgery - Abstract
Background The optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient– reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts. Methods Differences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria. Results The prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment (P < .05). There were no differences in brain volumes or cortical thickness between participants with and without cognitive impairment defined using the HAND and GDS measures. In contrast, those identified with cognitive impairment by the NMM had reduced mean cortical thickness in both hemispheres (P < .05), as well as smaller brain volumes (P < .01). The associations with measures of white matter microstructure and brain-predicted age generally were weaker. Conclusion Different methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach., We have previously described a novel multivariate method (NMM) with theoretical statistical advantages over existing methods, which we assessed here in 3 cohorts of people living with HIV. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status.
- Published
- 2019
5. 1640P Pegylated liposomal doxorubicin (PLD) as first line treatment in AIDS-related Kaposi’s sarcoma (AIDS-KS): A single institution retrospective study
- Author
-
Dalu, D., primary, Cona, M.S., additional, De Francesco, D., additional, Ammoni, L., additional, Rota, S., additional, Fasola, C., additional, Foschi, A., additional, and La Verde, N.M., additional
- Published
- 2020
- Full Text
- View/download PDF
6. Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers
- Author
-
van Zoest RA, Underwood J, De Francesco D, Sabin CA, Cole JH, Wit FW, Caan MWA, Kootstra NA, Fuchs D, Zetterberg H, Majoie CBLM, Portegies P, Winston A, Sharp DJ, Gisslén M, Reiss P, on behalf of the Comorbidity in Relation to AIDS Collaboration, Franceschi C, Garagnani P, Pirazzini C, Capri M, Dall'Olio F, Chiricolo M, Salvioli S., APH - Aging & Later Life, AII - Infectious diseases, Graduate School, Amsterdam institute for Infection and Immunity, Global Health, Radiology and Nuclear Medicine, Experimental Immunology, Amsterdam Cardiovascular Sciences, Infectious diseases, APH - Global Health, Other departments, Medical Psychology, Amsterdam Movement Sciences, Amsterdam Neuroscience - Neurodegeneration, APH - Mental Health, Medical Microbiology and Infection Prevention, Amsterdam Gastroenterology Endocrinology Metabolism, Laboratory for Endocrinology, Ophthalmology, Other Research, Cell Biology and Histology, APH - Digital Health, APH - Personalized Medicine, APH - Methodology, ACS - Microcirculation, ACS - Atherosclerosis & ischemic syndromes, ACS - Diabetes & metabolism, van Zoest RA, Underwood, J, De Francesco, D, Sabin, Ca, Cole, Jh, Wit, Fw, Caan, Mwa, Kootstra, Na, Fuchs, D, Zetterberg, H, Majoie, Cblm, Portegies, P, Winston, A, Sharp, Dj, Gisslén, M, Reiss, P, on behalf of the Comorbidity in Relation to AIDS Collaboration,, Franceschi, C, Garagnani, P, Pirazzini, C, Capri, M, Dall'Olio, F, Chiricolo, M, Salvioli, S., Commission of the European Communities, and Imperial College Healthcare NHS Trust- BRC Funding
- Subjects
Male ,medicine.medical_specialty ,Sustained Virologic Response ,HIV Infections ,Disease ,Gastroenterology ,Microbiology ,cerebrospinal fluid ,White matter ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Acquired immunodeficiency syndrome (AIDS) ,Internal medicine ,Antiretroviral Therapy, Highly Active ,Fractional anisotropy ,medicine ,Immunology and Allergy ,Humans ,030212 general & internal medicine ,neuroimaging ,business.industry ,Brain ,biomarkers ,HIV ,11 Medical And Health Sciences ,Middle Aged ,06 Biological Sciences ,medicine.disease ,Comorbidity ,Co-morBidity in Relation to AIDS (COBRA) Collaboration ,Infectious Diseases ,medicine.anatomical_structure ,neurofilament light chain ,Anti-Retroviral Agents ,Cohort ,biomarker ,Female ,Serostatus ,business ,030217 neurology & neurosurgery - Abstract
Background Brain structural abnormalities have been reported in persons living with human immunodeficiency virus (HIV; PLWH) who are receiving suppressive combination antiretroviral therapy (cART), but their pathophysiology remains unclear. Methods We investigated factors associated with brain tissue volumes and white matter microstructure (fractional anisotropy) in 134 PLWH receiving suppressive cART and 79 comparable HIV-negative controls, aged ≥45 years, from the Comorbidity in Relation to AIDS cohort, using multimodal neuroimaging and cerebrospinal fluid biomarkers. Results Compared with controls, PLWH had lower gray matter volumes (−13.7 mL; 95% confidence interval, −25.1 to −2.2) and fractional anisotropy (−0.0073; 95% confidence interval, −.012 to −.0024), with the largest differences observed in those with prior clinical AIDS. Hypertension and the soluble CD14 concentration in cerebrospinal fluid were associated with lower fractional anisotropy. These associations were independent of HIV serostatus (Pinteraction = .32 and Pinteraction = .59, respectively) and did not explain the greater abnormalities in brain structure in relation to HIV infection. Conclusions The presence of lower gray matter volumes and more white matter microstructural abnormalities in well-treated PLWH partly reflect a combination of historical effects of AIDS, as well as the more general influence of systemic factors, such as hypertension and ongoing neuroinflammation. Additional mechanisms explaining the accentuation of brain structure abnormalities in treated HIV infection remain to be identified.
- Published
- 2018
7. Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls
- Author
-
De Francesco, D., Underwood, J., Bagkeris, E., Boffito, M., Post, F. A., Mallon, P. W. G., Vera, J. H., Williams, I., Anderson, J., Johnson, M., Sabin, C. A., Winston, A., Babalis, Daphne, Boffito, Marta, Burgess, Laura, Mallon, Paddy, Sabin, Caroline, Sachikonye, Memory, Winston, Alan, Asboe, David, Garvey, Lucy, Pozniak, Anton, Clarke, Amanda, Vera, Jaime, Bexley, Andrew, Richardson, Celia, Kirk, Sarah, Gleig, Rebecca, Bracchi, Margherita, Pagani, Nicole, Cerrone, Maddalena, Bradshaw, Daniel, Ferretti, Francesca, Higgs, Chris, Seah, Elisha, Fletcher, Stephen, Anthonipillai, Michelle, Moyes, Ashley, Deats, Katie, Syed, Irtiza, Matthews, Clive, Fernando, Peter, Chiwome, Chido, Hardwick, Shane, Anderson, Jane, Mguni, Sifiso, Clark, Rebecca, Nevin-Dolan, Rhiannon, Pelluri, Sambasivarao, Post, Frank, Campbell, Lucy, Yurdakul, Selin, Okumu, Sara, Pollard, Louise, Santana-Suarez, Beatriz, Macken, Alan, Ghavani-Kia, Bijan, Maher, Joanne, Byrne, Maria, Flaherty, Ailbhe, Babu, Sumesh, Otiko, Damilola, Phillips, Laura, Laverick, Rosanna, Beynon, Michelle, Salz, Anna-Lena, Severn, Abigail, Tembo, Lavender, Stott, Matthew, McDonald, Linda, Dransfield, Felix, Whitehouse, Andrew, Ngwu, Nnenna, Hemat, Nargis, Jones, Martin, Carroll, Anne, Kinloch, Sabine, Youle, Mike, and Madge, Sara
- Subjects
0301 basic medicine ,Adult ,Male ,Substance-Related Disorders ,HIV Infections ,Hashish ,RC0109 ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Cognition ,cognitive disorder ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Effects of sleep deprivation on cognitive performance ,people living with HIV ,Life Style ,Depression (differential diagnoses) ,cognitive function ,Aged ,Original Research ,Depressive Disorder ,business.industry ,Health Policy ,Cognitive disorder ,HIV ,Middle Aged ,medicine.disease ,Recreational drug use ,030112 virology ,Mental health ,Patient Health Questionnaire ,Infectious Diseases ,Cross-Sectional Studies ,HIV‐associated neurocognitive disorders ,depression ,Female ,business ,medicine.drug ,Demography - Abstract
Objectives\ud We investigated whether differences in cognitive performance between people living with HIV (PLWH) and comparable HIV‐negative people were mediated or moderated by depressive symptoms and lifestyle factors.\ud \ud Methods\ud A cross‐sectional study of 637 ‘older’ PLWH aged ≥ 50 years, 340 ‘younger’ PLWH aged < 50 years and 276 demographically matched HIV‐negative controls aged ≥ 50 years enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study was performed. Cognitive function was assessed using a computerized battery (CogState). Scores were standardized into Z‐scores [mean = 0; standard deviation (SD) = 1] and averaged to obtain a global Z‐score. Depressive symptoms were evaluated via the Patient Health Questionnaire (PHQ‐9). Differences between the three groups and the effects of depression, sociodemographic factors and lifestyle factors on cognitive performance were evaluated using median regression. All analyses accounted for age, gender, ethnicity and level of education.\ud \ud Results\ud After adjustment for sociodemographic factors, older and younger PLWH had poorer overall cognitive scores than older HIV‐negative controls (P < 0.001 and P = 0.006, respectively). Moderate or severe depressive symptoms were more prevalent in both older (27%; P < 0.001) and younger (21%; P < 0.001) PLWH compared with controls (8%). Depressive symptoms (P < 0.001) and use of hashish (P = 0.01) were associated with lower cognitive function; alcohol consumption (P = 0.02) was associated with better cognitive scores. After further adjustment for these factors, the difference between older PLWH and HIV‐negative controls was no longer significant (P = 0.08), while that between younger PLWH and older HIV‐negative controls remained significant (P = 0.01).\ud \ud Conclusions\ud Poorer cognitive performances in PLWH compared with HIV‐negative individuals were, in part, mediated by the greater prevalence of depressive symptoms and recreational drug use reported by PLWH.
- Published
- 2019
8. Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment
- Author
-
Underwood, J, de Francesco, D, Cole, JH, Caan, MWA, van Zoest, RA, Schmand, BA, Sharp, DJ, Sabin, CA, Reiss, P, Winston, A, Wit, FWNM, Schouten, J, Kooij, KW, Elsenga, BC, Janssen, FR, Heidenrijk, M, Zikkenheiner, W, van der Valk, M, Kootstra, NA, Harskamp-Holwerda, AM, Maurer, I, Ruiz, MMM, Girigorie, AF, Villaudy, J, Frankin, E, Pasternak, A, Berkhout, B, van der Kuyl, T, Portegies, P, Geurtsen, GJ, ter Stege, JA, Twennaar, MK, Majoie, CBLM, Su, T, Weijer, K, Bisschop, PHLT, Kalsbeek, A, Wezel, M, Visser, I, Ruhe, HG, Franceschi, C, Garagnani, P, Pirazzini, C, Capri, M, Dall'Olio, F, Chiricolo, M, Salvioli, S, Hoeijmakers, J, Pothof, J, Prins, M, Martens, M, Moll, S, Berkel, J, Totte, M, Kovalev, S, Gisslen, M, Fuchs, D, Zetterberg, H, McDonald, L, Stott, M, Legg, K, Lovell, A, Erlwein, O, Doyle, N, Kingsley, C, Leech, R, Zaheri, S, Hillebregt, MMJ, Ruijs, YMC, Benschop, DP, Burger, D, de Graaff-Teulen, M, Guaraldi, G, Buerkle, A, Sindlinger, T, Moreno-Villanueva, M, Keller, A, Sabin, C, Libert, C, Dewaele, S, Boffito, M, Mallon, P, Post, F, Sachikonye, M, Anderson, J, Asboe, D, Garvey, L, Pozniak, A, Vera, J, Williams, I, Campbell, L, Yurdakul, S, Okumu, S, Pollard, L, Otiko, D, Phillips, L, Laverick, R, Fisher, M, Clarke, A, Bexley, A, Richardson, C, Macken, A, Ghavani-Kia, B, Maher, J, Byrne, M, Flaherty, A, Mguni, S, Clark, R, Nevin-Dolan, R, Pelluri, S, Johnson, M, Ngwu, N, Hemat, N, Jones, M, Carroll, A, Whitehouse, A, Burgess, L, Babalis, D, Higgs, C, Seah, E, Fletcher, S, Anthonipillai, M, Moyes, A, Deats, K, Syed, I, Matthews, C, Underwood, J, de Francesco, D, Cole, JH, Caan, MWA, van Zoest, RA, Schmand, BA, Sharp, DJ, Sabin, CA, Reiss, P, Winston, A, Wit, FWNM, Schouten, J, Kooij, KW, Elsenga, BC, Janssen, FR, Heidenrijk, M, Zikkenheiner, W, van der Valk, M, Kootstra, NA, Harskamp-Holwerda, AM, Maurer, I, Ruiz, MMM, Girigorie, AF, Villaudy, J, Frankin, E, Pasternak, A, Berkhout, B, van der Kuyl, T, Portegies, P, Geurtsen, GJ, ter Stege, JA, Twennaar, MK, Majoie, CBLM, Su, T, Weijer, K, Bisschop, PHLT, Kalsbeek, A, Wezel, M, Visser, I, Ruhe, HG, Franceschi, C, Garagnani, P, Pirazzini, C, Capri, M, Dall'Olio, F, Chiricolo, M, Salvioli, S, Hoeijmakers, J, Pothof, J, Prins, M, Martens, M, Moll, S, Berkel, J, Totte, M, Kovalev, S, Gisslen, M, Fuchs, D, Zetterberg, H, McDonald, L, Stott, M, Legg, K, Lovell, A, Erlwein, O, Doyle, N, Kingsley, C, Leech, R, Zaheri, S, Hillebregt, MMJ, Ruijs, YMC, Benschop, DP, Burger, D, de Graaff-Teulen, M, Guaraldi, G, Buerkle, A, Sindlinger, T, Moreno-Villanueva, M, Keller, A, Sabin, C, Libert, C, Dewaele, S, Boffito, M, Mallon, P, Post, F, Sachikonye, M, Anderson, J, Asboe, D, Garvey, L, Pozniak, A, Vera, J, Williams, I, Campbell, L, Yurdakul, S, Okumu, S, Pollard, L, Otiko, D, Phillips, L, Laverick, R, Fisher, M, Clarke, A, Bexley, A, Richardson, C, Macken, A, Ghavani-Kia, B, Maher, J, Byrne, M, Flaherty, A, Mguni, S, Clark, R, Nevin-Dolan, R, Pelluri, S, Johnson, M, Ngwu, N, Hemat, N, Jones, M, Carroll, A, Whitehouse, A, Burgess, L, Babalis, D, Higgs, C, Seah, E, Fletcher, S, Anthonipillai, M, Moyes, A, Deats, K, Syed, I, and Matthews, C
- Abstract
BACKGROUND: The optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient- reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts. METHODS: Differences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria. RESULTS: The prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment ( P < .05).There were no differences in brain volumes or cortical thickness between participants with and without cognitive impairment defined using the HAND and GDS measures. In contrast, those identified with cognitive impairment by the NMM had reduced mean cortical thickness in both hemispheres ( P < .05), as well as smaller brain volumes ( P < .01). The associations with measures of white matter microstructure and brain-predicted age generally were weaker. CONCLUSION: Different methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach.
- Published
- 2019
9. Strategies for preventing group B streptococcal infections in newborns: A nation-wide survey of Italian policies
- Author
-
Tzialla, C, berardi, A, farina, C, clerici, P, borghesi, A, viora, E, scollo, P, stronati, M, Task Force for group B streptococcal infections for the Italian Society of Neonatology including Stival, G, barbaglia, Ma, guala, A, giunta, E, parola, L, grossignani, Mr, perri, P, tubaldi, L, alletto, G, daidone, S, flacco, V, dani, C, sterpa, A, rapisardi, G, elicio, Mr, faldella, G, capretti, Mg, messner, H, bandiera, M, achille, C, azzali, A, montrasio, G, mariani, S, galvagno, G, giacosa, E, de Angelis, F, spandrio, M, serra, A, garofalo, F, perona, A, porcelli, F, ferrero, F, De Franco, S, paollilo, P, picone, S, besana, R, varisco, T, farina, M, memo, L, nicolini, G, lietti, D, Di Chiara, G, rottoli, A, Bonabitacola, T, Cortis, E, Neri, E, Martinelli, S, Ilardi, L, Rondanini, Gf, Calzi, P, Gatta, A, Quntadamo, Pa, Ivaldi, M, Terenzani, L, Di Lascio, N, Travaglio, Md, Vetrano, G, Furcolo, G, Vitacco, V, Intini, C, Frigerio, M, Stroppiana, P, Policicchio, G, Mesirca, P, Gianino, P, Audenio, E, Paludetto, R, Raimondi, F, Pugliese, A, Valentino, L, Nosari, N, Marchesano, G, Chirico, G, Bellù, R, Menchini, M, Poletti, A, E T, Vacchiano, Pinto, L, E D, Perri, Coppola, R, Perini, R, Vetrella, A, De Luca, G, Lista, G, Cavigioli, F, Bettinelli, A, Massironi, E, Franco, C, Bernardo, L, Poli, S, Palladini, M, Tota, V, Spadavecchia, F, Zuccotti, Gv, Pogliani, L, Bracaglia, G, Mancini, Al, Zocco, F, Iozzia, G, Auriemma, A, Teani, M, Mangilli, G, Tempra, Am, Di Terlizi, L, Bottino, R, Salvi, C, Fortunato, V, Musaico, R, Gargantini, G, Carrera, G, Magaldi, R, Taurino, L, D'Onofrio, Am, Buffone, E, Tempera, A, Agosti, M, Garzia, P, Mosca, F, Pugni, L, Tagliabue, P, Colombo, C, Demi, M, Picco, G, Carlucci, A, Zorzi, G, Padula, D, Cardone, Ml, Buonocore, G, Muraca, Mc, Boldrini, A, Ciantelli, M, Lanari, M, Serra, L, Felici, L, Banderalli, G, Brambilla, C, Dall'Agnola, A, Viviani, E, Zonca, Mc, Licardi, G, Chiara, A, Ancora, G, Papa, I, Gancia, P, Pomero, G, Deloglu, A, Villani, P, Mussini, P, Canidio, E, Migliavacca, D, Di Fabio, S, Cipollone, I, Biasucci, G, Rubbi, P, Piepoli, M, Guastaferro, N, Infriccioli, F, Bertino, E, Perathoner, C, Parmigiani, S, Suriano, G, Ianniello, C, Biasini, A, Azzalli, M, Timpani, G, Barresi, S, Caoci, G, Ciccotti, R, De Curtis, M, Natale, F, Finocchi, M, Haass, C, Milillo, F, Lucieri, S, Guercio, E, Canepa, Sa, Scozia, G, Antonucci, R, Limongelli, O, Macciò, S, Mongelli, F, Colonna, F, Dragovic, D, Calipa, Mt, Cohen, A, Moresco, L, Italian Society of Obstetricians and Gynecologists including La Spina, R, Ruggeri, R, Luehwink, A, Brattoli, M, Fedi, A, Lacchi, L, Ettore, G, Pappalardo, E, Conoscenti, G, Zeni, B, Spellecchia, D, Favretti, L, Spagna, L, Zaglio, S, Bresciani, D, Bandini, A, Mancini, R, Mustoni, P, Dodero, D, Grimaldi, M, Di Mario, M, Migliorini, P, Kemeny, A, Anastasio, Ps, Riccardi, T, Maggino, T, Cerri, G, Puggina, P, Marconi, Am, Morgia, S, Bellia, G, D'Anna, Mr, Catania, M, Bacchi Modena, A, Franchi, L, Calonaci, N, Schettini, S, Paradiso, R, Saccucci, P, Ioppi, M, Zorzi, M, Stellin, G, Patacchiola, F, Carrata, L, Bassini, D, San Marco, L, Todros, T, Tibadi, C, Liborio, M, Italian Association of Clinical Microbiologists including Laricchia, R, Tauro, L, Ferrara, F, Nuara, C, Ghiraldi, E, Molinari, F, Comessatti, A, Rocchetti, A, Di Matteo, L, Miconi, V, Calvi, P, Pernigotti, A, Fabozzi, F, Micca, G, Monticone, G, Sarti, M, Da Rin, G, Zoppelletto, M, Modolo, E, Landini, Mp, Furlini, G, Galluppi, E, Pagani, E, Aschbacher, R, Innocenti, P, Bresolin, N, Raggi, Me, Bonfanti, C, De Francesco, M, Santer, P, Griessmaier, A, De Francesco, D, Pirali, A, Prasciolu, C, Usai, F, Cuzzone, G, Scutellà, M, Tramacere, P, Fossati, D, Piaserico, G, Bordignon, G, Sciacca, A, Di Vincenzo, F, Imbriani, A, Melotti, D, Catanoso, G, Rivetti, I, Neri, G, Bruno, R, Bacelle, L, Sartore, P, Giana, G, Sala, E, Giraldi, C, Cavalcanti, P, Perugini, M, Perugini, A, Ginardi, C, Maritano, D, Ferrini, A, Bonettini, A, Avanzini, A, Gasperoni, S, Pieretti, B, Montanari, E, Carillo, C, Rossi, Mr, Laureti, A, Baldoni, Ml, Serra, D, Melioli, G, Bandettini, R, Oneto, F, Colla, R, Storchi Incerti, S, Lanzini, F, Pauri, P, Tili, E, Leone, Ra, Verdastro, G, Megha, M, Luzzaro, F, Conti, A, Busulini, L, Mirri, P, Diodati, R, Vettori, C, Pittalis, S, Anesi, A, Fiore, A, Goglia, L, Vitullo, E, Sinno, A, Platzgummer, S, Spitaler, C, Trabucchi, Mc, Besozzi, M, Cesana, E, Inghilleri, G, Grosso, S, D'Angelo, R, Fogato, E, Lavarda, F, Ortisi, G, Clementi, M, Cichero, P, Rumpianesi, F, Venturelli, C, Mortillaro, F, Daffara, S, Catania, Mr, Iula, D, Andreoni, S, Politi, A, Agostinelli, C, Paparella, C, Capozzi, D, Notaris, P, Bistoni, F, Mencacci, A, Valentini, M, Filippetti, A, Confalonieri, M, Novarese, O, Bonini, F, Salamone, D, Camporese, A, De Rosa, R, Casprini, P, Degl'Innocenti, R, Giordano, R, Allù, Mt, Zanella, D, Malandrino, M, Tronci, M, Valmarin, M, Leonetti, G, Falco, S, Meledandri, M, Ballardini, M, Spanò, A, Cava, Mc, Mascellino, Mt, Schinella, M, Gualdi, P, Casari, E, Scattolo, N, Motta, C, Perfetti, C, Bassano, M, Cera, G, Iafisco, P, Mura, I, Palmieri, A, Migliardi, M, Ferlini, M, Grandi, G, Giardini, F, Albano, F, Latino, M, Ferrero, Mp, Bellizia, L, Russolo, M, Russolo, S, Pesenti, A, Fasano, Ma, Previato, S, Radillo, O, Busetti, M, Ferrari, P, Siderini, V, Puzzolante, L, Scarparo, C, Arzese, A, Cappuccia, N, Lodolo, L, Delledonne, L, Gramoni, A, Maiolo, V, Gheller, A, Spadaro, S, Balzaretti, M, Tzialla, C., Berardi, A., Farina, C., Clerici, P., Borghesi, A., Viora, E., Scollo, P., Stronati, M., Stival, G., Barbaglia, M. A., Guala, A., Giunta, E., Parola, L., Grossignani, M. R., Perri, P., Tubaldi, L., Alletto, G., Daidone, S., Flacco, V., Dani, C., Sterpa, A., Rapisardi, G., Elicio, M. R., Faldella, G., Capretti, M. G., Messner, H., Bandiera, M., Achille, C., Azzali, A., Montrasio, G., Mariani, S., Galvagno, G., Giacosa, E., de Angelis, F., Spandrio, M., Serra, A., Garofalo, F., Perona, A., Porcelli, F., Ferrero, F., De Franco, S., Paollilo, P., Picone, S., Besana, R., Varisco, T., Farina, M., Memo, L., Nicolini, G., Lietti, D., Di Chiara, G., Rottoli, A., Bonabitacola, T., Cortis, E., Neri, E., Martinelli, S., Ilardi, L., Rondanini, G. F., Calzi, P., Gatta, A., Quntadamo, P. A., Ivaldi, M., Terenzani, L., Di Lascio, N., Travaglio, M. D., Vetrano, G., Furcolo, G., Vitacco, V., Intini, C., Frigerio, M., Stroppiana, P., Policicchio, G., Mesirca, P., Gianino, P., Audenio, E., Paludetto, R., Raimondi, F., Pugliese, A., Valentino, L., Nosari, N., Marchesano, G., Chirico, G., Bell(`u), R., Menchini, M., Poletti, A., Vacchiano, T., Pinto, L., Perri, D., Coppola, R., Perini, R., Vetrella, A., De Luca, G., Lista, G., Cavigioli, F., Bettinelli, A., Massironi, E., Franco, C., Bernardo, L., Poli, S., Palladini, M., Tota, V., Spadavecchia, F., Zuccotti, G. V., Pogliani, L., Bracaglia, G., Mancini, A. L., Zocco, F., Iozzia, G., Auriemma, A., Teani, M., Mangilli, G., Tempra, A. M., Di Terlizi, L., Bottino, R., Salvi, C., Fortunato, V., Musaico, R., Gargantini, G., Carrera, G., Magaldi, R., Taurino, L., D?onofrio, A. M., Buffone, E., Tempera, A., Agosti, M., Garzia, P., Mosca, F., Pugni, L., Tagliabue, P., Colombo, C., Demi, M., Picco, G., Carlucci, A., Zorzi, G., Padula, D., Cardone, M. L., Buonocore, G., Muraca, M. C., Boldrini, A., Ciantelli, M., Lanari, M., Serra, L., Felici, L., Banderalli, G., Brambilla, C., Dall?agnola, A., Viviani, E., Zonca, M. C., Licardi, G., Chiara, A., Ancora, G., Papa, I., Gancia, P., Pomero, G., Deloglu, A., Villani, P., Mussini, P., Canidio, E., Migliavacca, D., Di Fabio, S., Cipollone, I., Biasucci, G., Rubbi, P., Piepoli, M., Guastaferro, N., Infriccioli, F., Bertino, E., Perathoner, C., Parmigiani, S., Suriano, G., Ianniello, C., Biasini, A., Azzalli, M., Timpani, G., Barresi, S., Caoci, G., Ciccotti, R., De Curtis, M., Natale, F., Finocchi, M., Haass, C., Milillo, F., Lucieri, S., Guercio, E., Canepa, S. A., Scozia, G., Antonucci, R., Limongelli, O., Macci(`o), S., Mongelli, F., Colonna, F., Dragovic, D., Calipa, M. T., Cohen, A., Moresco, L., La Spina, R., Ruggeri, R., Luehwink, A., Brattoli, M., Fedi, A., Lacchi, L., Ettore, G., Pappalardo, E., Conoscenti, G., Zeni, B., Spellecchia, D., Favretti, L., Spagna, L., Zaglio, S., Bresciani, D., Bandini, A., Mancini, R., Mustoni, P., Dodero, D., Grimaldi, M., Di Mario, M., Migliorini, P., Kemeny, A., Anastasio, P. S., Riccardi, T., Maggino, T., Cerri, G., Puggina, P., Marconi, A. M., Morgia, S., Bellia, G., D?anna, M. R., Catania, M., Bacchi Modena, A., Franchi, L., Calonaci, N., Schettini, S., Paradiso, R., Saccucci, P., Ioppi, M., Zorzi, M., Stellin, G., Patacchiola, F., Carrata, L., Bassini, D., San Marco, L., Todros, T., Tibadi, C., Liborio, M., Laricchia, R., Tauro, L., Ferrara, F., Nuara, C., Ghiraldi, E., Molinari, F., Comessatti, A., Rocchetti, A., Di Matteo, L., Miconi, V., Calvi, P., Pernigotti, A., Fabozzi, F., Micca, G., Monticone, G., Sarti, M., Da Rin, G., Zoppelletto, M., Modolo, E., Landini, M. P., Furlini, G., Galluppi, E., Pagani, E., Aschbacher, R., Innocenti, P., Bresolin, N., Raggi, M. E., Bonfanti, C., De Francesco, M., Santer, P., Griessmaier, A., De Francesco, D., Pirali, A., Prasciolu, C., Usai, F., Cuzzone, G., Scutell(`a), M., Tramacere, P., Fossati, D., Piaserico, G., Bordignon, G., Sciacca, A., Di Vincenzo, F., Imbriani, A., Melotti, D., Catanoso, G., Rivetti, I., Neri, G., Bruno, R., Bacelle, L., Sartore, P., Giana, G., Sala, E., Giraldi, C., Cavalcanti, P., Perugini, M., Perugini, A., Ginardi, C., Maritano, D., Ferrini, A., Bonettini, A., Avanzini, A., Gasperoni, S., Pieretti, B., Montanari, E., Carillo, C., Rossi, M. R., Laureti, A., Baldoni, M. L., Serra, D., Melioli, G., Bandettini, R., Oneto, F., Colla, R., Storchi Incerti, S., Lanzini, F., Pauri, P., Tili, E., Leone, R. A., Verdastro, G., Megha, M., Luzzaro, F., Conti, A., Busulini, L., Mirri, P., Diodati, R., Vettori, C., Pittalis, S., Anesi, A., Fiore, A., Goglia, L., Vitullo, E., Sinno, A., Platzgummer, S., Spitaler, C., Trabucchi, M. C., Besozzi, M., Cesana, E., Inghilleri, G., Grosso, S., D?angelo, R., Fogato, E., Lavarda, F., Ortisi, G., Clementi, M., Cichero, P., Rumpianesi, F., Venturelli, C., Mortillaro, F., Daffara, S., Catania, M. R., Iula, D., Andreoni, S., Politi, A., Agostinelli, C., Paparella, C., Capozzi, D., Notaris, P., Bistoni, F., Mencacci, A., Valentini, M., Filippetti, A., Confalonieri, M., Novarese, O., Bonini, F., Salamone, D., Camporese, A., De Rosa, R., Casprini, P., Degl?innocenti, R., Giordano, R., All(`u), M. T., Zanella, D., Malandrino, M., Tronci, M., Valmarin, M., Leonetti, G., Falco, S., Meledandri, M., Ballardini, M., Span(`o), A., Cava, M. C., Mascellino, M. T., Schinella, M., Gualdi, P., Casari, E., Scattolo, N., Motta, C., Perfetti, C., Bassano, M., Cera, G., Iafisco, P., Mura, I., Palmieri, A., Migliardi, M., Ferlini, M., Grandi, G., Giardini, F., Albano, F., Latino, M., Ferrero, M. P., Bellizia, L., Russolo, M., Russolo, S., Pesenti, A., Fasano, M. A., Previato, S., Radillo, O., Busetti, M., Ferrari, P., Siderini, V., Puzzolante, L., Scarparo, C., Arzese, A., Cappuccia, N., Lodolo, L., Delledonne, L., Gramoni, A., Maiolo, V., Gheller, A., Spadaro, S., Balzaretti, M., Tzialla, Chryssoula, Berardi, Alberto, Farina, Claudio, Clerici, Pierangelo, Borghesi, Alessandro, Viora, Elsa, Scollo, Paolo, Stronati, Mauro, [.., Lanari, Marcello, Faldella, Giacomo, and ]
- Subjects
Male ,Pediatrics ,Group B ,0302 clinical medicine ,Neonate ,Pregnancy ,Surveys and Questionnaires ,Prevalence ,Mass Screening ,Blood culture ,030212 general & internal medicine ,Antibiotic prophylaxis ,Survey ,GBS ,Group B streptococcus ,Infection ,Newborn infant ,Adult ,Antibiotic Prophylaxis ,Female ,Health Surveys ,Humans ,Infant, Newborn ,Italy ,Neonatal Screening ,Pregnancy Complications, Infectious ,Prenatal Care ,Primary Prevention ,Risk Assessment ,Streptococcal Infections ,Streptococcus agalactiae ,reproductive and urinary physiology ,Group B streptococcu ,medicine.diagnostic_test ,lcsh:RJ1-570 ,Infectious ,Perinatology and Child Health ,Pediatrics, Perinatology and Child Health ,medicine.medical_specialty ,Antibiotic sensitivity ,Group B Streptococcal Infection ,Prenatal care ,03 medical and health sciences ,030225 pediatrics ,medicine ,Intensive care medicine ,Mass screening ,business.industry ,Public health ,Infant ,lcsh:Pediatrics ,Newborn ,Pregnancy Complications ,business - Abstract
Background There are no Italian data regarding the strategies for preventing neonatal group B streptococcal (GBS) infection. We conducted a national survey in order to explore obstetrical, neonatal and microbiological practices for the GBS prevention. Methods Three distinct questionnaires were sent to obstetricians, neonatologists and microbiologists. Questionnaires included data on prenatal GBS screening, maternal risk factors, intrapartum antibiotic prophylaxis, microbiological information concerning specimen processing and GBS antimicrobial susceptibility. Results All respondent obstetrical units used the culture-based screening approach to identify women who should receive intrapartum antibiotic prophylaxis, and more than half of the microbiological laboratories (58%) reported using specimen processing consistent with CDC guidelines. Most neonatal units (89 out of 107, 82%) reported using protocols for preventing GBS early-onset sepsis consistent with CDC guidelines. Conclusions The screening-based strategy is largely prevalent in Italy, and most protocols for preventing GBS early-onset sepsis are consistent with CDC guidelines. However, we found discrepancies in practices among centers that may reflect the lack of Italian guidelines issued by public health organizations.
- Published
- 2017
10. Non-Hodgkin lymphoma in HIV-positive patients treated with antiretroviral therapy and chemotherapy: A single institution retrospective study
- Author
-
Dalu, D., primary, Fasola, C., additional, De Francesco, D., additional, Bombonati, G., additional, Ammoni, L., additional, and La Verde, N.M., additional
- Published
- 2019
- Full Text
- View/download PDF
11. Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of cognitive impairment
- Author
-
Underwood, J, Leech, R, Winston, A, Sabin, C, and De Francesco, D
- Subjects
Science & Technology ,Infectious Diseases ,Virology ,1103 Clinical Sciences ,Life Sciences & Biomedicine - Published
- 2017
12. Grey and white matter abnormalities in treated HIV-disease and their relationship to cognitive function
- Author
-
Underwood, J, Cole, JH, Caan, M, De Francesco, D, Leech, R, Van Zoest, RA, Su, T, Geurtsen, GJ, Schmand, BA, Portegies, P, Prins, M, Wit, FW, Sabin, CA, Majoie, C, Reiss, P, Winston, A, Sharp, DJ, Co-morBidity in Relation to Aids (COBRA) Collaboration, Commission of the European Communities, National Institute for Health Research, and Imperial College Healthcare NHS Trust- BRC Funding
- Subjects
Science & Technology ,neuroimaging ,Immunology ,HIV ,11 Medical And Health Sciences ,IMPAIRMENT ,06 Biological Sciences ,diffusion tensor imaging ,Microbiology ,PREVALENCE ,INTEGRITY ,INDIVIDUALS ,Infectious Diseases ,ANTIRETROVIRAL THERAPY ,HIV-INFECTION ,NEUROCOGNITIVE DISORDERS ,REGISTRATION ,voxel-based morphometry ,COHORT ,Comorbidity in Relation to AIDS (COBRA) Collaboration ,BRAIN ,Life Sciences & Biomedicine ,cognitive impairment - Abstract
Background: Long-term comorbidities such as cognitive impairment remain prevalent in otherwise effectively treated people-living-with-HIV. We investigate the relationship between cognitive impairment and brain structure in successfully treated patients using multi-modal neuroimaging from the Co-morBidity in Relation to AIDS (COBRA) cohort. Methods: Cognitive function, brain tissue volumes and white matter microstructure were assessed in 134 HIV-positive patients and 79 controls. All patients had suppressed plasma HIV RNA at cohort entry. In addition to comprehensive voxelwise analyses of volumetric and diffusion tensor imaging, we used an unsupervised machine learning approach to combine cognitive, diffusion and volumetric data, taking advantage of the complementary information they provide. Results: Compared to the highly comparable control group, cognitive function was impaired in four out of the six cognitive domains tested (median global T-scores: 50.8 vs. 54.2, p
- Published
- 2017
13. Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV
- Author
-
Underwood, J, De Francesco, D, Post, FA, Vera, JH, Williams, I, Boffito, M, Mallon, PW, Anderson, J, Sachikonye, M, Sabin, C, Winston, A, and Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study group
- Subjects
Gerontology ,Male ,Activities of daily living ,HIV Infections ,03 medical and health sciences ,0302 clinical medicine ,Cognition ,Acquired immunodeficiency syndrome (AIDS) ,Surveys and Questionnaires ,Virology ,Medicine ,Dementia ,Humans ,Pharmacology (medical) ,Cognitive Dysfunction ,030212 general & internal medicine ,Prospective Studies ,VALIDITY ,Depression (differential diagnoses) ,Aged ,cognitive impairment ,Aged, 80 and over ,Science & Technology ,business.industry ,Health Policy ,HIV ,1103 Clinical Sciences ,Middle Aged ,medicine.disease ,Mental health ,3. Good health ,NEUROPSYCHOLOGICAL IMPAIRMENT ,Sexual desire ,Infectious Diseases ,patient-reported outcomes ,Normative ,Female ,business ,activities of daily living ,Life Sciences & Biomedicine ,030217 neurology & neurosurgery - Abstract
Objectives: While cognitive impairment is frequently reported in HIV-positive individuals and has historically been associated with poorer functional outcomes, the associations between cognitive impairment and patient-reported outcome measures (PROMs) in contemporary cohorts are unclear.\ud \ud Methods: We tested cognitive function using a computerized battery (CogState™) in 290 HIV-positive and 97 HIV-negative individuals aged ≥ 50 years participating in the Pharmacokinetic and Clinical Observations in People Over Fifty (POPPY) study. Participants completed questionnaires detailing physical and mental health [Short Form Health Survey (SF-36)], cognitive function [European AIDS Clinical Society (EACS) questions], activities of daily living [Lawton Instrumental Activities of Daily Living (IADL)], depression [Patient Depression Questionnaire (PHQ-9) and Centres for Epidemiologic Studies Depression scale (CES-D)], falls and sexual desire. Cognitive impairment was defined using the Frascati criteria, global deficit score (GDS) and multivariate normative comparison (MNC). In the HIV-positive group, the classification performances of the different definitions of cognitive impairment and dichotomized questionnaire results were calculated.\ud \ud Results: The prevalence of cognitive impairment in the HIV-positive group was 34.5% (GDS), 30.0% (Frascati) and 22.1% (MNC), with only 2% diagnosed with HIV-associated dementia. In general, the associations between cognitive impairment and PROMs were weak regardless of the definition used: mean c-statistics were 0.543 (GDS), 0.530 (MNC) and 0.519 (Frascati). Associations were similar using the global T-score to define cognitive impairment. Summary health scores (SF-36) were lower, but only significantly so for those with cognitive impairment identified using MNC, for both mental health (61.4 vs. 75.8; P = 0.03) and physical health (60.9 vs. 75.0; P = 0.03).\ud \ud Conclusions: The associations between cognitive impairment and PROMs were weak, possibly because impairment was mild and therefore largely asymptomatic. Further work is needed to elucidate the clinical implications of cognitive impairment in HIV-disease.
- Published
- 2016
14. Brain MRI changes associated with poorer cognitive function despite suppressive antiretroviral therapy
- Author
-
Underwood, J, Cole, JH, Sharp, D, Winston, A, Leech, R, Majoie, C, Caan, M, De Francesco, D, Van Zoest, R, Geurtsen, G, Schmand, B, Wit, F, Reiss, P, Sabin, C, and Commission of the European Communities
- Subjects
Science & Technology ,Infectious Diseases ,Virology ,1103 Clinical Sciences ,Life Sciences & Biomedicine - Published
- 2016
15. Genetic Factors Associated with Platinum Toxicity: A Preliminary Study
- Author
-
De Troia, B., primary, Davide, D., additional, Filipazzi, V., additional, Isabella, L., additional, Tosca, N., additional, Ferrario, S., additional, Gambaro, A., additional, Somma, L., additional, Fasola, C., additional, Pellegrini, I., additional, Bombonati, G., additional, Damiani, E., additional, Cheli, S., additional, Falvella, F.S., additional, Clementi, E., additional, de Francesco, D., additional, and Cattaneo, M.T., additional
- Published
- 2017
- Full Text
- View/download PDF
16. American College of Cardiology pooled equations and DAD algorithm to predict freedom from cardiovascular events in HIV patients
- Author
-
Guaraldi, Giovanni, De Francesco, D, Malagoli, Andrea, Manicardi, Marcella, Zona, Stefano, Stentarelli, Chiara, Carli, Federica, Santoro, Antonella, and Raggi, P.
- Subjects
cardiovascular risk ,HIV infection ,HIV infection, cardiovascular risk - Published
- 2015
17. Clinical evaluation is better than risk prediction algorithms to identify patients who need statin therapy
- Author
-
Guaraldi, Giovanni, De Francesco, D, Malagoli, Andrea, Manicardi, Marcella, Zona, Stefano, Stentarelli, Chiara, Carli, Federica, Menozzi, Marianna, Mussini, Cristina, and Raggi, P.
- Subjects
cardiovascular risk ,statin ,HIV infection ,HIV infection, cardiovascular risk, statin - Published
- 2015
18. 1068PD - Non-Hodgkin lymphoma in HIV-positive patients treated with antiretroviral therapy and chemotherapy: A single institution retrospective study
- Author
-
Dalu, D., Fasola, C., De Francesco, D., Bombonati, G., Ammoni, L., and La Verde, N.M.
- Published
- 2019
- Full Text
- View/download PDF
19. Progetto junk-paccottiglia. Studio etnoarcheologico dei processi formativi potenziali di una superficie urbana contemporanea a frequentazione intensiva
- Author
-
Maini E., Giorgio L., Guerrini S., Balsassarri P., de Francesco D., Cardinale F., Vidale M., and Maini E., Giorgio L., Guerrini S., Balsassarri P., de Francesco D., Cardinale F., Vidale M.
- Subjects
Parco dei Caduti ,Parco dei Caduti, Quartiere San Lorenzo, superficie urbana, modelli teorici, Junk-Paccottiglia ,Quartiere San Lorenzo ,superficie urbana ,Junk-Paccottiglia ,modelli teorici - Abstract
The processes of loss, the throwing away and abandonment of small handmade items in present-day areas generally result in the formation of ephemeral and unsedinzented contexts. Only a very small part of what is lost or discarded will, in fact, contribute to the formation of well-consolidated and permanent archaeological layers in the place where they were aban¬doned. The "Junk-Paccottiglia" Project is centred on the archaeological study of a modern park in the centre of Rome and has involved the observation, the collection and the spatial contextualization of about 1500 archaeological items in the space of 14 months, from September 2004 to December 2005. Surveys conducted almost daily have permitted the collection of hundreds of personal ornaments (hair clips, beads, pendants, earrings, studs, buttons, artificial nails, gadgets for mobile phones, etc.). The items have then been quantitatively and qualitatively classified on the basis of shape, dimensions and material, with attention paid to the location where they were found and to the categories of age and sex of the population to which they probably belonged. The archaeology of contemporary beads is extremely complex in terms of defining their original owners. In the case of necklaces and bracelets that had fallen on the ground and that were lost or only partial¬ly recovered, the process of recovery of these elements and the dimensions of the areas of distribution were studied on the basis of some preliminary parameters, such as the average dimensions and spherical coefficient of the beads. Seasonal indicators such as buttons lost in the park, which vary in dimension and colour according to the current climate, have also enabled us to evaluate the chronological and seasonal variability of the processes of archaeological formation and distribution in space. This was carried out on the basis of climatic variation and consideration of exposure to sunlight and shade. These aspects are, in fact, a universal variable of human behaviour Finally, the archaeological expression of certain ritual behaviours, specifically connected to recurrent and well-recognizable chronological occurrences, has been supported.
- Published
- 2007
20. Retrospective analysis of patients affected by diffuse large B cell lymphomas AIDS-related
- Author
-
Latocca, M.M., primary, Dalu, D., additional, Fasola, C., additional, Filipazzi, V., additional, Ferrario, S., additional, Tosca, N., additional, Brioschi, F., additional, Bandera, A., additional, Verga, L., additional, De Francesco, D., additional, and Piazza, E., additional
- Published
- 2016
- Full Text
- View/download PDF
21. The Role of Women in the New Millennium Entrepreneurship
- Author
-
Rosati, Simona, DE FRANCESCO, D., Filipponi, D., and Fontana, Renato
- Published
- 2011
22. Statistical Information and Mass Media: the Diffusion of Census Data in the last 150th Years
- Author
-
Rosati, Simona, DE FRANCESCO, D, Conti, C., and Tononi, A. M.
- Published
- 2011
23. Hierarchical modeling of indoor radon concentration: How much do geology and building factors matter?
- Author
-
Borgoni, R, De Francesco, D, DE BARTOLO, D, Tzavidis, N, BORGONI, RICCARDO, DE BARTOLO, DANIELA CARMELA, Tzavidis, N., Borgoni, R, De Francesco, D, DE BARTOLO, D, Tzavidis, N, BORGONI, RICCARDO, DE BARTOLO, DANIELA CARMELA, and Tzavidis, N.
- Abstract
Radon is a natural gas known to be the main contributor to natural background radiation exposure and only second to smoking as major leading cause of lung cancer. The main concern is in indoor environments where the gas tends to accumulate and can reach high concentrations. The primary contributor of this gas into the building is from the soil although architectonic characteristics, such as building materials, can largely affect concentration values. Understanding the factors affecting the concentration in dwellings and workplaces is important both in prevention, when the construction of a new building is being planned, and in mitigation when the amount of Radon detected inside a building is too high. In this paper we investigate how several factors, such as geologic typologies of the soil and a range of building characteristics, impact on indoor concentration focusing, in particular, on how concentration changes as a function of the floor level. Adopting a mixed effects model to account for the hierarchical nature of the data, we also quantify the extent to which such measurable factors manage to explain the variability of indoor radon concentration
- Published
- 2014
24. T8 - Genetic Factors Associated with Platinum Toxicity: A Preliminary Study
- Author
-
De Troia, B., Davide, D., Filipazzi, V., Isabella, L., Tosca, N., Ferrario, S., Gambaro, A., Somma, L., Fasola, C., Pellegrini, I., Bombonati, G., Damiani, E., Cheli, S., Falvella, F.S., Clementi, E., de Francesco, D., and Cattaneo, M.T.
- Published
- 2017
- Full Text
- View/download PDF
25. S45 - Retrospective analysis of patients affected by diffuse large B cell lymphomas AIDS-related
- Author
-
Latocca, M.M., Dalu, D., Fasola, C., Filipazzi, V., Ferrario, S., Tosca, N., Brioschi, F., Bandera, A., Verga, L., De Francesco, D., and Piazza, E.
- Published
- 2016
- Full Text
- View/download PDF
26. Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital.
- Author
-
Malacrida, V, De Francesco, D, Banfi, G, Porta, F A, and Riches, P G
- Abstract
Protein electrophoresis was carried out on 102,000 samples from the patients of a district general hospital over 10 years, and a monoclonal protein was detected in 730 cases; of these, 114 could be classified as B cell malignancies and 261 as monoclonal gammopathy of undefined significance (MGUS). The various clinical and laboratory features of monoclonal gammopathy were examined with respect to distinguishing the malignant conditions from MGUS at first presentation. [ABSTRACT FROM PUBLISHER]
- Published
- 1987
27. Antiretroviral central nervous system toxicity
- Author
-
Underwood, J., De Francesco, D., Cole, J., Wit, F., Sharp, D., Sabin, C., Reiss, P., Winston, A., Underwood, J., De Francesco, D., Cole, J., Wit, F., Sharp, D., Sabin, C., Reiss, P., and Winston, A.
28. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell- associated HIV RNA and DNA levels compared to protease inhibitor-based therapy
- Author
-
O Erlwein, A Winston, Peter Reiss, J Villaudy, B Berkhout, M. van der Valk, DP Benschop, A Kalsbeek, Ben Berkhout, M Martens, C Kingsley, T Booiman, Neeltje A. Kootstra, M Wezel, M Moreno-Villanueva, Paolo Garagnani, N Doyle, S Salvioli, BC Elsenga, JA ter Stege, T van der Kuyl, T Su, FR Janssen, BA Schmand, MM Mangas Ruiz, T Sindlinger, I Maurer, A Bürkle, M Capri, W Zikkenheiner, C Libert, M Chiricolo, Robert Leech, Ferdinand Wnm Wit, J Pothof, Caroline A. Sabin, Cblm Majoie, M Gisslén, A Lovell, Mmj Hillebregt, S Zaheri, I Visser, Claudio Franceschi, M de Graaff-Teulen, Alexander O. Pasternak, S Kovalev, M Prins, M Totté, NA Kootstra, H Zetterberg, D de Francesco, JH Cole, K Legg, Mwa Caan, J Schouten, M Klein Twennaar, Jelmer Vroom, J Berkel, AF Girigorie, P Reiss, S Moll, S Dewaele, K Weijer, D Fuchs, Marijn de Bruin, Alan Winston, Chiara Pirazzini, R.A. van Zoest, F Dall'Olio, Davide De Francesco, David J. Sharp, A Keller, AM Harskamp-Holwerda, J Underwood, F. W. Wit, GJ Geurtsen, P Portegies, Ymc Ruijs, M Stott, Margreet Bakker, M Heidenrijk, KW Kooij, Phlt Bisschop, G Guaraldi, L McDonald, C Sabin, AO Pasternak, J Hoeijmakers, Jan M. Prins, HG Ruhé, E Frankin, D Burger, Commission of the European Communities, National Institute for Health Research, and Pasternak AO, Vroom J, Kootstra NA, Wit FW, de Bruin M, De Francesco D, Bakker M, Sabin CA, Winston A, Prins JM, Reiss P, Berkhout B. Collaboratori C Franceschi, P Garagnani, C Pirazzini, M Capri, F Dall'Olio, M Chiricolo, S Salvioli
- Subjects
Life Sciences & Biomedicine - Other Topics ,DYNAMICS ,Male ,PROVIRUSES PRODUCE ,medicine ,Time Factors ,Co-morBidity in Relation to Aids (COBRA) Collaboration ,HIV Infections ,Virus Replication ,0601 Biochemistry and Cell Biology ,Nucleoside Reverse Transcriptase Inhibitor ,chemistry.chemical_compound ,Transcription (biology) ,virus infection ,Biology (General) ,Randomized Controlled Trials as Topic ,INFECTED PATIENTS ,Reverse-transcriptase inhibitor ,General Neuroscience ,virus diseases ,General Medicine ,Middle Aged ,Viral Load ,Europe ,Treatment Outcome ,viru ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,Life Sciences & Biomedicine ,medicine.drug ,Adult ,antiviral drug ,Nevirapine ,Efavirenz ,QH301-705.5 ,RALTEGRAVIR INTENSIFICATION ,Science ,infectious disease ,VIREMIA ,virus ,General Biochemistry, Genetics and Molecular Biology ,Virus ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,antiviral drugs ,All institutes and research themes of the Radboud University Medical Center ,Humans ,Protease inhibitor (pharmacology) ,Biology ,Science & Technology ,General Immunology and Microbiology ,business.industry ,PERSISTENCE ,microbiology ,RNA ,HIV ,HIV Protease Inhibitors ,Virology ,IMMUNE ACTIVATION ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Cross-Sectional Studies ,chemistry ,REPLICATION ,DNA, Viral ,RESERVOIR ,business ,DECAY - Abstract
Background:It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress human immunodeficiency virus (HIV) replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI).Methods:CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n = 100, n = 124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either an NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically measured adherence to ART.Results:In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho = 0.70 and rho = 0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj = 0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj = 0.048 and padj = 0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals.Conclusions:All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size.Funding:This work was supported by ZonMw (09120011910035) and FP7 Health (305522).
- Published
- 2021
29. Hierarchical modeling of indoor radon concentration: how much do geology and building factors matter?
- Author
-
Davide De Francesco, Nikos Tzavidis, Daniela de Bartolo, Riccardo Borgoni, Borgoni, R, De Francesco, D, DE BARTOLO, D, and Tzavidis, N
- Subjects
Pollution ,Health, Toxicology and Mutagenesis ,media_common.quotation_subject ,chemistry.chemical_element ,Radon ,Soil ,Natural gas ,Floor effect ,Environmental Chemistry ,Waste Management and Disposal ,Background radiation ,media_common ,Hierarchical modeling ,business.industry ,Construction Materials ,Soil gas ,Environmental engineering ,Floor level ,General Medicine ,Indoor radon concentration ,Models, Theoretical ,Building factor ,Residential radon ,Construction Material ,Hierarchical mixed model ,chemistry ,Italy ,Air Pollutants, Radioactive ,Air Pollution, Indoor ,Housing ,business ,Geology - Abstract
Radon is a natural gas known to be the main contributor to natural background radiation exposure and only second to smoking as major leading cause of lung cancer. The main concern is in indoor environments where the gas tends to accumulate and can reach high concentrations. The primary contributor of this gas into the building is from the soil although architectonic characteristics, such as building materials, can largely affect concentration values. Understanding the factors affecting the concentration in dwellings and workplaces is important both in prevention, when the construction of a new building is being planned, and in mitigation when the amount of Radon detected inside a building is too high. In this paper we investigate how several factors, such as geologic typologies of the soil and a range of building characteristics, impact on indoor concentration focusing, in particular, on how concentration changes as a function of the floor level. Adopting a mixed effects model to account for the hierarchical nature of the data, we also quantify the extent to which such measurable factors manage to explain the variability of indoor radon concentration.
- Published
- 2014
30. Hospital-Based Influenza and Pneumococcal Vaccination for Cancer Patients on Active Treatment and Their Family Members during the COVID-19 Pandemic in Italy: A Single-Center Experience.
- Author
-
Dalu D, Ridolfo AL, Ruggieri L, Cona MS, Riva A, De Francesco D, Tricella C, Fasola C, Ferrario S, Gambaro A, Lombardi Stocchetti B, Smiroldo V, Rebecchi G, Piva S, Carrozzo G, Antinori S, and La Verde N
- Abstract
In patients with cancer, tumor- and treatment-induced immunosuppression are responsible for a four-fold increase in morbidity and mortality caused by influenza and invasive Streptococcus pneumoniae infections compared to the general population. The main oncology societies strongly recommend vaccination in patients with cancer to prevent these infections. However, vaccine hesitancy is a main concern in this population. The aim of this study was to assess the feasibility of in-hospital vaccination for patients under anticancer treatment and their family members (FMs) against influenza and pneumococcal infections during the COVID-19 pandemic in order to increase vaccine coverage. This was a single-center, prospective, observational study conducted at the Department of Oncology of Luigi Sacco University Hospital (Milan, Italy) between October 2020 and April 2021. The main primary outcome was the incidence of influenza-like illness (ILI) and pneumococcal infections. The main secondary outcome was safety. A total of 341 subjects were enrolled, including 194 patients with cancer and 147 FMs. The incidence of ILI was higher among patients than among FMs (9% vs. 2.7%, OR 3.92, p = 0.02). Moreover, two subjects were diagnosed with pneumococcal pneumonia. The most frequent vaccine-related AEs were pain in the injection site (31%) and fatigue (8.7%). In conclusion, this hospital-based vaccination strategy was feasible during the COVID-19 pandemic, representing a potential model to maximize vaccine coverage during a public health emergency.
- Published
- 2024
- Full Text
- View/download PDF
31. Deep representation learning identifies associations between physical activity and sleep patterns during pregnancy and prematurity.
- Author
-
Ravindra NG, Espinosa C, Berson E, Phongpreecha T, Zhao P, Becker M, Chang AL, Shome S, Marić I, De Francesco D, Mataraso S, Saarunya G, Thuraiappah M, Xue L, Gaudillière B, Angst MS, Shaw GM, Herzog ED, Stevenson DK, England SK, and Aghaeepour N
- Abstract
Preterm birth (PTB) is the leading cause of infant mortality globally. Research has focused on developing predictive models for PTB without prioritizing cost-effective interventions. Physical activity and sleep present unique opportunities for interventions in low- and middle-income populations (LMICs). However, objective measurement of physical activity and sleep remains challenging and self-reported metrics suffer from low-resolution and accuracy. In this study, we use physical activity data collected using a wearable device comprising over 181,944 h of data across N = 1083 patients. Using a new state-of-the art deep learning time-series classification architecture, we develop a 'clock' of healthy dynamics during pregnancy by using gestational age (GA) as a surrogate for progression of pregnancy. We also develop novel interpretability algorithms that integrate unsupervised clustering, model error analysis, feature attribution, and automated actigraphy analysis, allowing for model interpretation with respect to sleep, activity, and clinical variables. Our model performs significantly better than 7 other machine learning and AI methods for modeling the progression of pregnancy. We found that deviations from a normal 'clock' of physical activity and sleep changes during pregnancy are strongly associated with pregnancy outcomes. When our model underestimates GA, there are 0.52 fewer preterm births than expected (P = 1.01e - 67, permutation test) and when our model overestimates GA, there are 1.44 times (P = 2.82e - 39, permutation test) more preterm births than expected. Model error is negatively correlated with interdaily stability (P = 0.043, Spearman's), indicating that our model assigns a more advanced GA when an individual's daily rhythms are less precise. Supporting this, our model attributes higher importance to sleep periods in predicting higher-than-actual GA, relative to lower-than-actual GA (P = 1.01e - 21, Mann-Whitney U). Combining prediction and interpretability allows us to signal when activity behaviors alter the likelihood of preterm birth and advocates for the development of clinical decision support through passive monitoring and exercise habit and sleep recommendations, which can be easily implemented in LMICs., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
32. Cross-species comparative analysis of single presynapses.
- Author
-
Berson E, Gajera CR, Phongpreecha T, Perna A, Bukhari SA, Becker M, Chang AL, De Francesco D, Espinosa C, Ravindra NG, Postupna N, Latimer CS, Shively CA, Register TC, Craft S, Montine KS, Fox EJ, Keene CD, Bendall SC, Aghaeepour N, and Montine TJ
- Subjects
- Humans, Animals, Mice, Cerebral Cortex, Lipid Metabolism, Macaca, Synaptic Transmission, Brain
- Abstract
Comparing brain structure across species and regions enables key functional insights. Leveraging publicly available data from a novel mass cytometry-based method, synaptometry by time of flight (SynTOF), we applied an unsupervised machine learning approach to conduct a comparative study of presynapse molecular abundance across three species and three brain regions. We used neural networks and their attractive properties to model complex relationships among high dimensional data to develop a unified, unsupervised framework for comparing the profile of more than 4.5 million single presynapses among normal human, macaque, and mouse samples. An extensive validation showed the feasibility of performing cross-species comparison using SynTOF profiling. Integrative analysis of the abundance of 20 presynaptic proteins revealed near-complete separation between primates and mice involving synaptic pruning, cellular energy, lipid metabolism, and neurotransmission. In addition, our analysis revealed a strong overlap between the presynaptic composition of human and macaque in the cerebral cortex and neostriatum. Our unique approach illuminates species- and region-specific variation in presynapse molecular composition., (© 2023. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
33. Percutaneous Vertebral Reconstruction (PVR) Technique of Pathological Compression Fractures: An Innovative Combined Treatment of Microwave Ablation, Bilateral Expandable Titanium SpineJack Implants Followed by Vertebroplasty.
- Author
-
Pusceddu C, Marsico S, Derudas D, Ballicu N, Melis L, Zedda S, de Felice C, Calabrese A, De Francesco D, Venturini M, Santucci D, and Faiella E
- Abstract
(1) Background: to retrospectively evaluate safety and efficacy of combined microwave ablation (MWA) and bilateral expandable titanium SpineJack (SJ) implants followed by vertebroplasty (VP) for the treatment of painful thoracolumbar pathological vertebral compression fracture. (2) Methods: from July 2017 to October 2022, twenty-eight patients (13 women and 15 men; mean age 68 ± 11 years) with a history of primary neoplasm and thirty-six painful vertebral metastases with vertebral compression fracture underwent combined MWA and bilateral expandable titanium SpineJack implants with vertebroplasty. We analyzed safety through complications rate, and efficacy through vertebral height restoration and pain decrease, evaluated using a visual analogue scale (VAS), and Functional Mobility Scale (FMS), and local tumor control. Contrast-enhanced CT scans were performed at 1, 3, and 6 months and a contrast-enhanced spine MRI at 6 months after the procedure. (3) Results: Technical success rate was 100%. No procedure-related major complications or death occurred. Vertebral height restoration was observed in 22 levels (58%), with a mean anterior height restoration of 2.6 mm ± 0.6 and a mean middle height restoration of 4.4 mm ± 0.6 ( p < 0.001). Mean VAS score of pain evaluation on the day before treatment was 6.3 ± 1.5 (range 4-9). At the 6-month evaluation, the median VAS score for pain was 0.4 ± 0.6 (range 0-2) with a mean reduction of 93.65% (6.8 ± 0.7 vs. 0.4 ± 0.6; p < 0.000) compared with baseline evaluation. Contrast-enhanced CT scans were performed at 1, 3, and 6 months and a contrast-enhanced spine MRI was performed at 6 months after the procedure, showing no local recurrence, implant displacement, or new fractures in the treated site. (4) Conclusions: combined microwave ablation and bilateral expandable titanium SpineJack implants with vertebroplasty is a safe and effective procedure for the treatment of pathological compressive vertebral fractures. The vertebral stabilization achieved early and persistent pain relief, increasing patient mobility, improving recovery of walking capacity, and providing local tumor control.
- Published
- 2023
- Full Text
- View/download PDF
34. Multiomic signals associated with maternal epidemiological factors contributing to preterm birth in low- and middle-income countries.
- Author
-
Espinosa CA, Khan W, Khanam R, Das S, Khalid J, Pervin J, Kasaro MP, Contrepois K, Chang AL, Phongpreecha T, Michael B, Ellenberger M, Mehmood U, Hotwani A, Nizar A, Kabir F, Wong RJ, Becker M, Berson E, Culos A, De Francesco D, Mataraso S, Ravindra N, Thuraiappah M, Xenochristou M, Stelzer IA, Marić I, Dutta A, Raqib R, Ahmed S, Rahman S, Hasan ASMT, Ali SM, Juma MH, Rahman M, Aktar S, Deb S, Price JT, Wise PH, Winn VD, Druzin ML, Gibbs RS, Darmstadt GL, Murray JC, Stringer JSA, Gaudilliere B, Snyder MP, Angst MS, Rahman A, Baqui AH, Jehan F, Nisar MI, Vwalika B, Sazawal S, Shaw GM, Stevenson DK, and Aghaeepour N
- Subjects
- Infant, Newborn, Pregnancy, Child, Humans, Female, Developing Countries, Multiomics, Proteomics, Chemokines, CC, Premature Birth epidemiology
- Abstract
Preterm birth (PTB) is the leading cause of death in children under five, yet comprehensive studies are hindered by its multiple complex etiologies. Epidemiological associations between PTB and maternal characteristics have been previously described. This work used multiomic profiling and multivariate modeling to investigate the biological signatures of these characteristics. Maternal covariates were collected during pregnancy from 13,841 pregnant women across five sites. Plasma samples from 231 participants were analyzed to generate proteomic, metabolomic, and lipidomic datasets. Machine learning models showed robust performance for the prediction of PTB (AUROC = 0.70), time-to-delivery ( r = 0.65), maternal age ( r = 0.59), gravidity ( r = 0.56), and BMI ( r = 0.81). Time-to-delivery biological correlates included fetal-associated proteins (e.g., ALPP, AFP, and PGF) and immune proteins (e.g., PD-L1, CCL28, and LIFR). Maternal age negatively correlated with collagen COL9A1, gravidity with endothelial NOS and inflammatory chemokine CXCL13, and BMI with leptin and structural protein FABP4. These results provide an integrated view of epidemiological factors associated with PTB and identify biological signatures of clinical covariates affecting this disease.
- Published
- 2023
- Full Text
- View/download PDF
35. Revealing the impact of lifestyle stressors on the risk of adverse pregnancy outcomes with multitask machine learning.
- Author
-
Becker M, Dai J, Chang AL, Feyaerts D, Stelzer IA, Zhang M, Berson E, Saarunya G, De Francesco D, Espinosa C, Kim Y, Marić I, Mataraso S, Payrovnaziri SN, Phongpreecha T, Ravindra NG, Shome S, Tan Y, Thuraiappah M, Xue L, Mayo JA, Quaintance CC, Laborde A, King LS, Dhabhar FS, Gotlib IH, Wong RJ, Angst MS, Shaw GM, Stevenson DK, Gaudilliere B, and Aghaeepour N
- Abstract
Psychosocial and stress-related factors (PSFs), defined as internal or external stimuli that induce biological changes, are potentially modifiable factors and accessible targets for interventions that are associated with adverse pregnancy outcomes (APOs). Although individual APOs have been shown to be connected to PSFs, they are biologically interconnected, relatively infrequent, and therefore challenging to model. In this context, multi-task machine learning (MML) is an ideal tool for exploring the interconnectedness of APOs on the one hand and building on joint combinatorial outcomes to increase predictive power on the other hand. Additionally, by integrating single cell immunological profiling of underlying biological processes, the effects of stress-based therapeutics may be measurable, facilitating the development of precision medicine approaches., Objectives: The primary objectives were to jointly model multiple APOs and their connection to stress early in pregnancy, and to explore the underlying biology to guide development of accessible and measurable interventions., Materials and Methods: In a prospective cohort study, PSFs were assessed during the first trimester with an extensive self-filled questionnaire for 200 women. We used MML to simultaneously model, and predict APOs (severe preeclampsia, superimposed preeclampsia, gestational diabetes and early gestational age) as well as several risk factors (BMI, diabetes, hypertension) for these patients based on PSFs. Strongly interrelated stressors were categorized to identify potential therapeutic targets. Furthermore, for a subset of 14 women, we modeled the connection of PSFs to the maternal immune system to APOs by building corresponding ML models based on an extensive single cell immune dataset generated by mass cytometry time of flight (CyTOF)., Results: Jointly modeling APOs in a MML setting significantly increased modeling capabilities and yielded a highly predictive integrated model of APOs underscoring their interconnectedness. Most APOs were associated with mental health, life stress, and perceived health risks. Biologically, stressors were associated with specific immune characteristics revolving around CD4/CD8 T cells. Immune characteristics predicted based on stress were in turn found to be associated with APOs., Conclusions: Elucidating connections among stress, multiple APOs simultaneously, and immune characteristics has the potential to facilitate the implementation of ML-based, individualized, integrative models of pregnancy in clinical decision making. The modifiable nature of stressors may enable the development of accessible interventions, with success tracked through immune characteristics., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (© 2022 Becker, Dai, Chang, Feyaerts, Stelzer, Zhang, Berson, Saarunya, De Francesco, Espinosa, Kim, Marić, Mataraso, Payrovnaziri, Phongpreecha, Ravindra, Shome, Tan, Thuraiappah, Xue, Mayo, Quaintance, Laborde, King, Dhabhar, Gotlib, Wong, Angst, Shaw, Stevenson, Gaudilliere and Aghaeepour.)
- Published
- 2022
- Full Text
- View/download PDF
36. Early prediction and longitudinal modeling of preeclampsia from multiomics.
- Author
-
Marić I, Contrepois K, Moufarrej MN, Stelzer IA, Feyaerts D, Han X, Tang A, Stanley N, Wong RJ, Traber GM, Ellenberger M, Chang AL, Fallahzadeh R, Nassar H, Becker M, Xenochristou M, Espinosa C, De Francesco D, Ghaemi MS, Costello EK, Culos A, Ling XB, Sylvester KG, Darmstadt GL, Winn VD, Shaw GM, Relman DA, Quake SR, Angst MS, Snyder MP, Stevenson DK, Gaudilliere B, and Aghaeepour N
- Abstract
Preeclampsia is a complex disease of pregnancy whose physiopathology remains unclear. We developed machine-learning models for early prediction of preeclampsia (first 16 weeks of pregnancy) and over gestation by analyzing six omics datasets from a longitudinal cohort of pregnant women. For early pregnancy, a prediction model using nine urine metabolites had the highest accuracy and was validated on an independent cohort (area under the receiver-operating characteristic curve [AUC] = 0.88, 95% confidence interval [CI] [0.76, 0.99] cross-validated; AUC = 0.83, 95% CI [0.62,1] validated). Univariate analysis demonstrated statistical significance of identified metabolites. An integrated multiomics model further improved accuracy (AUC = 0.94). Several biological pathways were identified including tryptophan, caffeine, and arachidonic acid metabolisms. Integration with immune cytometry data suggested novel associations between immune and proteomic dynamics. While further validation in a larger population is necessary, these encouraging results can serve as a basis for a simple, early diagnostic test for preeclampsia., Competing Interests: S.R.Q. is a founder, consultant, and shareholder of Mirvie. M.N.M. is a shareholder of Mirvie. D.A.R. is a shareholder of Blue Willow Biologics, Cantata Bio, Evelo Biosciences, Karius, Proderm IQ, and Second Genome. D.A.R. is an advisor to Cantata Bio and Visby Medical. K.G.S. is paid advisor of Mission Biocapital and Infinant Health; equity holder and paid advisor of Avexegen; and equity holder of mProbe. M.P.S. is a co-founder and scientific advisor of Personalis, SensOmics, Qbio, January AI, Fodsel, Filtricine, Protos, RTHM, Iollo, Marble Therapeutics, and Mirvie, and a scientific advisor of Genapsys, Jupiter, Neuvivo, Swaza, and Mitrix., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
37. Safety and Feasibility of Steerable Radiofrequency Ablation in Combination with Cementoplasty for the Treatment of Large Extraspinal Bone Metastases.
- Author
-
Pusceddu C, De Francesco D, Ballicu N, Santucci D, Marsico S, Venturini M, Fior D, Moramarco LP, and Faiella E
- Subjects
- Feasibility Studies, Humans, Pain etiology, Quality of Life, Retrospective Studies, Treatment Outcome, Bone Neoplasms surgery, Catheter Ablation adverse effects, Cementoplasty adverse effects, Cementoplasty methods
- Abstract
Background: Radiofrequency ablation (RFA) and cementoplasty, individually and in concert, has been adopted as palliative interventional strategies to reduce pain caused by bone metastases and prevent skeletal related events. We aim to evaluate the feasibility and safety of a steerable RFA device with an articulating bipolar extensible electrode for the treatment of extraspinal bone metastases. Methods: All data were retrospectively reviewed. All the ablation procedures were performed using a steerable RFA device (STAR, Merit Medical Systems, Inc., South Jordan, UT, USA). The pain was assessed with a VAS score before treatment and at 1-week and 3-, 6-, and 12-month follow-up. The Functional Mobility Scale (FMS) was recorded preoperatively and 1 month after the treatment through a four-point scale (4, bedridden; 3, use of wheelchair; 2, limited painful ambulation; 1, normal ambulation). Technical success was defined as successful intraoperative ablation and cementoplasty without major complications. Results: A statistically significant reduction of the median VAS score before treatment and 1 week after RFA and cementoplasty was observed (p < 0.001). A total of 6/7 patients who used a wheelchair reported normal ambulation 1 month after treatment. All patients with limited painful ambulation reported normal ambulation after the RFA and cementoplasty (p = 0.003). Technical success was achieved in all the combined procedures. Two cement leakages were reported. No local recurrences were observed after 1 year. Conclusions: The combined treatment of RFA with a steerable device and cementoplasty is a safe, feasible, and promising clinical option for the management of painful bone metastases, challenging for morphology and location, resulting in an improvement of the quality of life of patients.
- Published
- 2022
- Full Text
- View/download PDF
38. A data-driven health index for neonatal morbidities.
- Author
-
De Francesco D, Blumenfeld YJ, Marić I, Mayo JA, Chang AL, Fallahzadeh R, Phongpreecha T, Butwick AJ, Xenochristou M, Phibbs CS, Bidoki NH, Becker M, Culos A, Espinosa C, Liu Q, Sylvester KG, Gaudilliere B, Angst MS, Stevenson DK, Shaw GM, and Aghaeepour N
- Abstract
Whereas prematurity is a major cause of neonatal mortality, morbidity, and lifelong impairment, the degree of prematurity is usually defined by the gestational age (GA) at delivery rather than by neonatal morbidity. Here we propose a multi-task deep neural network model that simultaneously predicts twelve neonatal morbidities, as the basis for a new data-driven approach to define prematurity. Maternal demographics, medical history, obstetrical complications, and prenatal fetal findings were obtained from linked birth certificates and maternal/infant hospitalization records for 11,594,786 livebirths in California from 1991 to 2012. Overall, our model outperformed traditional models to assess prematurity which are based on GA and/or birthweight (area under the precision-recall curve was 0.326 for our model, 0.229 for GA, and 0.156 for small for GA). These findings highlight the potential of using machine learning techniques to predict multiple prematurity phenotypes and inform clinical decisions to prevent, diagnose and treat neonatal morbidities., Competing Interests: The authors declare no competing interests., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
39. Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study.
- Author
-
Alagaratnam J, De Francesco D, Zetterberg H, Heslegrave A, Toombs J, Kootstra NA, Underwood J, Gisslen M, Reiss P, Fidler S, Sabin CA, and Winston A
- Subjects
- Anti-Retroviral Agents therapeutic use, Biomarkers cerebrospinal fluid, Comorbidity, Humans, Intermediate Filaments, HIV Infections complications, HIV Infections drug therapy, Neurofilament Proteins blood, Neurofilament Proteins cerebrospinal fluid
- Abstract
Cerebrospinal fluid (CSF) neurofilament light protein (NfL) is a marker of central nervous system neuro-axonal injury. A novel, ultra-sensitive assay can determine plasma NfL. In untreated people-with-HIV (PWH), CSF and plasma NfL are strongly correlated. We aimed to assess this correlation in PWH on suppressive antiretroviral treatment (ART) and lifestyle-similar HIV-negative individuals enrolled into the COmorBidity in Relation to AIDS (COBRA) study. Differences in paired CSF (sandwich ELISA, UmanDiagnostics) and plasma (Simoa digital immunoassay, Quanterix™) NfL between PWH and HIV-negative participants were tested using Wilcoxon's test; associations were assessed using Pearson's correlation. CSF and plasma NfL, standardised to Z-scores, were included as dependent variables in linear regression models to identify factors independently associated with values in PWH and HIV-negative participants. Overall, 132 PWH (all with plasma HIV RNA < 50 copies/mL) and 79 HIV-negative participants were included. Neither CSF (median 570 vs 568 pg/mL, p = 0.37) nor plasma (median 10.7 vs 9.9 pg/mL, p = 0.15) NfL differed significantly between PWH and HIV-negative participants, respectively. CSF and plasma NfL correlated moderately, with no significant difference by HIV status (PWH: rho = 0.52; HIV-negative participants: rho = 0.47, p (interaction) = 0.63). In multivariable regression analysis, higher CSF NfL Z-score was statistically significantly associated with older age and higher CSF protein, and higher plasma NfL Z-score with older age, higher serum creatinine and lower bodyweight. In conclusion, in PWH on ART, the correlation between CSF and plasma NfL is moderate and similar to that observed in lifestyle-similar HIV-negative individuals. Consideration of renal function and bodyweight may be required when utilising plasma NfL., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
40. The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-Reach Spinal Metastases.
- Author
-
Pusceddu C, De Francesco D, Melis L, Ballicu N, and Fancellu A
- Subjects
- Humans, Neoplasm Recurrence, Local, Retrospective Studies, Spine, Catheter Ablation, Radiofrequency Ablation, Spinal Neoplasms surgery
- Abstract
Aims: The purpose of this study was to assess the effectiveness of a navigational radiofrequency ablation device with concurrent vertebral augmentation in the treatment of posterior vertebral body metastatic lesions, which are technically difficult to access. Primary outcomes of the study were evaluation of pain palliation and radiologic assessment of local tumor control., Materials and Methods: Thirty-five patients with 41 vertebral spinal metastases involving the posterior vertebral body underwent computed tomography-guided percutaneous targeted radiofrequency ablation, with a navigational radiofrequency ablation device, associated with vertebral augmentation. Twenty-one patients (60%) had 1 or 2 metastatic lesions (Group A) and fourteen (40%) patients had multiple (>2) vertebral lesions (Group B). Changes in pain severity were evaluated by visual analog scale (VAS). Metastatic lesions were evaluated in terms of radiological local control., Results: The procedure was technically successful in all the treated vertebrae. Among the symptomatic patients, the mean VAS score dropped from 5.7 (95% CI 4.9-6.5) before tRFA and to 0.9 (95% CI 0.4-1.3) after tRFA ( p < 0.001). The mean decrease in VAS score between baseline and one week follow up was 4.8 (95% CI 4.2-5.4). VAS decrease over time between one week and one year following radiofrequency ablation was similar, suggesting that pain relief was immediate and durable. Neither patients with 1-2 vertebral metastases, nor those with multiple lesions, showed radiological signs of local progression or recurrence of the tumor in the index vertebrae during a median follow up of 19 months (4-46 months) and 10 months (4-37 months), respectively., Conclusion: Treatment of spinal metastases with a navigational radiofrequency ablation device and vertebral augmentation can be used to obtain local tumor control with immediate and durable pain relief, providing effective treatment in the multimodality management of difficult-to-reach spinal metastases.
- Published
- 2021
- Full Text
- View/download PDF
41. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy.
- Author
-
Pasternak AO, Vroom J, Kootstra NA, Wit FW, de Bruin M, De Francesco D, Bakker M, Sabin CA, Winston A, Prins JM, Reiss P, and Berkhout B
- Subjects
- Adult, Cross-Sectional Studies, Drug Therapy, Combination, Europe, Female, HIV genetics, HIV growth & development, HIV Infections diagnosis, HIV Infections virology, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Viral Load, DNA, Viral genetics, HIV drug effects, HIV Infections drug therapy, HIV Protease Inhibitors therapeutic use, RNA, Viral genetics, Reverse Transcriptase Inhibitors therapeutic use, Virus Replication drug effects
- Abstract
Background: It remains unclear whether combination antiretroviral therapy (ART) regimens differ in their ability to fully suppress human immunodeficiency virus (HIV) replication. Here, we report the results of two cross-sectional studies that compared levels of cell-associated (CA) HIV markers between individuals receiving suppressive ART containing either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI)., Methods: CA HIV unspliced RNA and total HIV DNA were quantified in two cohorts (n = 100, n = 124) of individuals treated with triple ART regimens consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) plus either an NNRTI or a PI. To compare CA HIV RNA and DNA levels between the regimens, we built multivariable models adjusting for age, gender, current and nadir CD4
+ count, plasma viral load zenith, duration of virological suppression, NRTI backbone composition, low-level plasma HIV RNA detectability, and electronically measured adherence to ART., Results: In both cohorts, levels of CA HIV RNA and DNA strongly correlated (rho = 0.70 and rho = 0.54) and both markers were lower in NNRTI-treated than in PI-treated individuals. In the multivariable analysis, CA RNA in both cohorts remained significantly reduced in NNRTI-treated individuals (padj = 0.02 in both cohorts), with a similar but weaker association between the ART regimen and total HIV DNA (padj = 0.048 and padj = 0.10). No differences in CA HIV RNA or DNA levels were observed between individual NNRTIs or individual PIs, but CA HIV RNA was lower in individuals treated with either nevirapine or efavirenz, compared to PI-treated individuals., Conclusions: All current classes of antiretroviral drugs only prevent infection of new cells but do not inhibit HIV RNA transcription in long-lived reservoir cells. Therefore, these differences in CA HIV RNA and DNA levels by treatment regimen suggest that NNRTIs are more potent in suppressing HIV residual replication than PIs, which may result in a smaller viral reservoir size., Funding: This work was supported by ZonMw (09120011910035) and FP7 Health (305522)., Competing Interests: AP, JV, NK, FW, Md, DD, MB, CS, AW, JP, PR, BB No competing interests declared, (© 2021, Pasternak et al.)- Published
- 2021
- Full Text
- View/download PDF
42. Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.
- Author
-
De Francesco D, Wang X, Dickinson L, Underwood J, Bagkeris E, Babalis DS, Mallon PWG, Post FA, Vera JH, Sachikonye M, Williams I, Khoo S, Sabin CA, Winston A, and Boffito M
- Subjects
- AIDS Dementia Complex blood, AIDS Dementia Complex drug therapy, AIDS Dementia Complex prevention & control, Anti-HIV Agents pharmacology, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cross-Sectional Studies, Drug Therapy, Combination, Female, HIV Infections blood, HIV Infections psychology, Humans, Male, Mental Status and Dementia Tests, Middle Aged, Reverse Transcriptase Inhibitors pharmacology, Reverse Transcriptase Inhibitors therapeutic use, Socioeconomic Factors, Viral Load, Anti-HIV Agents blood, Cognition drug effects, HIV Infections drug therapy, Reverse Transcriptase Inhibitors blood
- Abstract
Objectives: To investigate the associations of plasma lamivudine (3TC), abacavir (ABC), emtricitabine (FTC) and tenofovir (TFV) concentrations with cognitive function in a cohort of treated people with HIV (PWH)., Methods: Pharmacokinetics (PK) and cognitive function (Cogstate, six domains) data were obtained from PWH recruited in the POPPY study on either 3TC/ABC or FTC/tenofovir disoproxil fumarate (TDF)-containing regimens. Association between PK parameters (AUC0-24: area under the concentration-time curve over 24 hours, Cmax: maximum concentration and Ctrough: trough concentration) and cognitive scores (standardized into z-scores) were evaluated using rank regression adjusting for potential confounders., Results: Median (IQR) global cognitive z-scores in the 83 PWH on 3TC/ABC and 471 PWH on FTC/TDF were 0.14 (-0.27, 0.38) and 0.09 (-0.28, 0.42), respectively. Higher 3TC AUC0-24 and Ctrough were associated with better global z-scores [rho = 0.29 (p = 0.02) and 0.27 (p = 0.04), respectively], whereas higher 3TC Cmax was associated with poorer z-scores [rho = -0.31 (p<0.01)], independently of ABC concentrations. Associations of ABC PK parameters with global and domain z-scores were non-significant after adjustment for confounders and 3TC concentrations (all p's>0.05). None of the FTC and TFV PK parameters were associated with global or domain cognitive scores., Conclusions: Whilst we found no evidence of either detrimental or beneficial effects of ABC, FTC and TFV plasma exposure on cognitive function of PWH, higher plasma 3TC exposures were generally associated with better cognitive performance although higher peak concentrations were associated with poorer performance., Competing Interests: F.P. has received grants from Gilead, ViiV and Janssen and personal fees from Gilead, ViiV and MSD. C.S. has received funding from Gilead Sciences, ViiV Healthcare, and Janssen-Cilag for membership of data safety and monitoring boards, advisory boards, and speaker panels and preparation of educational materials. A.W. has received honoraria or research grants from VIiV Healthcare, Gilead Sciences, BMS, Merck and Co. and Janssen. M.B. has received speaker fees from Gilead, MSD/Merck and Janssen, advisory fees from ViiV, Gilead and MSD/Merck, honoraria from Gilead for speakers’ bureau and a travel grant from Gilead, and has been the principal investigator in clinical trials sponsored by Gilead, ViiV, Mylan, Janssen and Bristol-Meyers Squibb. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2021
- Full Text
- View/download PDF
43. Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis.
- Author
-
Alagaratnam J, von Widekind S, De Francesco D, Underwood J, Edison P, Winston A, Zetterberg H, and Fidler S
- Abstract
Objective: To assess the overall pooled correlation coefficient estimate between cerebrospinal fluid (CSF) and blood neurofilament light (NfL) protein., Methods: We searched Medline, Embase and Web of Science for published articles, from their inception to 9 July 2019, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Studies reporting the correlation between CSF and blood NfL in humans were included. We conducted a random-effects meta-analysis to calculate the overall pooled correlation coefficient estimate, accounting for correlation technique and assay used. Heterogeneity was assessed using the I
2 statistic test. In sensitivity analyses, we calculated the pooled correlation coefficient estimate according to blood NfL assay: single-molecule array digital immunoassay (Simoa), electrochemiluminescence (ECL) assay or ELISA., Results: Data were extracted from 36 articles, including 3961 paired CSF and blood NfL samples. Overall, 26/36 studies measured blood NfL using Simoa, 8/36 ECL, 1/36 ELISA and 1 study reported all three assay results. The overall meta-analysis demonstrated that the pooled correlation coefficient estimate for CSF and blood NfL was r=0.72. Heterogeneity was significant: I2 =83%, p<0.01. In sensitivity analyses, the pooled correlation coefficient was similar for studies measuring blood NfL using Simoa and ECL (r=0.69 and r=0.68, respectively) but weaker for ELISA (r=0.35)., Conclusion: Moderate correlations are demonstrated between CSF and blood NfL, especially when blood NfL was measured using Simoa and ECL. Given its high analytical sensitivity, Simoa is the preferred assay for measuring NfL, especially at low or physiological concentrations, and this meta-analysis supports its use as the current most advanced surrogate measure of CSF NfL., Prospero Registration Number: CRD42019140469., Competing Interests: Competing interests: JA has received financial support to attend scientific conferences from MSD and Gilead Sciences. JU has received honoraria for preparation of educational materials and has served on an advisory board for Gilead Sciences. PE has received grants from the Medical Research Council, Alzheimer’s Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Association, Alzheimer’s Society, Novo Nordisk®, Life Molecular Imaging, GE Healthcare, Eli Lilly and Company, Novartis International AG and NIHR Imperial Biomedical Research Centre (BRC). PE was also a consultant to Pfizer, is now a consultant to Novo Nordisk, and serves on the advisory board for Novo Nordisk. PE has received consultancy and speaker fees from Piramal Life Sciences, Pfizer and Novo Nordisk. AW has received honoraria or research grants on behalf of Imperial College London or been a consultant or investigator in clinical trials sponsored by Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Roche and ViiV Healthcare. HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (outside submitted work). SF received funding and research grants from the National Institutes of Health (NIH), Bill & Melinda Gates Foundation (BMGF) and Medical Research Council (MRC)., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2021
- Full Text
- View/download PDF
44. Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals.
- Author
-
De Francesco D, Sabin CA, Winston A, Mallon PWG, Anderson J, Boffito M, Doyle ND, Haddow L, Post FA, Vera JH, Sachikonye M, Redline S, and Kunisaki KM
- Subjects
- Cross-Sectional Studies, Humans, Life Style, Male, Self Report, Sleep, HIV Infections complications
- Abstract
Objectives: The aim of this study was to evaluate the agreement between self-reported sleep measures and insomnia with objectively measured sleep parameters in people with HIV (PWH) and HIV-negative individuals., Design: A cross-sectional analysis of PWH and lifestyle-similar HIV-negative individuals., Methods: Self-reported measures included time spent in bed, sleep onset latency and a validated insomnia questionnaire. Objective measures were assessed via 7-days/nights of actigraphy data to determine average and intra-individual variability of several sleep measures (including time spent in bed and onset latency). Spearman's correlation coefficient and Cohen's κ were used to assess the agreement between self-reported and actigraphy-assessed measures. Associations between insomnia and actigraphy-assessed sleep parameters were evaluated using partial least-square discriminant analysis (PLS-DA)., Results: We found fair correlation between self-reported and actigraphy-assessed time spent in bed in 342 PWH (rs = 0.46) and 119 HIV-negative individuals (rs = 0.48). Among PWH, the correlation did not differ by age, education, depressive symptoms and self-reported insomnia (all P > 0.05), but was stronger in men (P = 0.05) and in those with a BMI of at least 25 kg/m2 (P < 0.001). Agreement between self-reported and actigraphy-assessed sleep onset latency was poor in both PWH (κ = 0.002, P = 0.49) and HIV-negative individuals (κ = 0.009, P = 0.65). According to PLS-DA, self-reported insomnia most strongly correlated with intra-individual variability of sleep duration, movement index and efficiency., Conclusion: We report poor-to-fair agreement between self-reported and actigraphy-assessed sleep measures in PWH. Insomnia symptoms correlated with regularity of sleep duration, quality and efficiency. These findings highlight the importance of both patient-reported and objective measures of daily sleep variation, for better understanding sleep disorders in PWH., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
45. Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study.
- Author
-
Kunisaki KM, De Francesco D, Sabin CA, Winston A, Mallon PWG, Anderson J, Bagkeris E, Boffito M, Doyle N, Haddow L, Post FA, Sachikonye M, Vera J, Khalil W, and Redline S
- Abstract
Background: Self-reported sleep quality is poor in persons with human immunodeficiency virus (PWH), but prior studies commonly used nonspecific questionnaires, investigated only single sleep disorders, or lacked human immunodeficiency virus (HIV)-negative controls. We addressed these limitations in the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Sleep Substudy by assessing PWH and HIV-negative controls for insomnia, restless legs syndrome (RLS), and sleep apnea (SA)., Methods: Previously enrolled POPPY participants coenrolled in this substudy without regard to sleep symptoms. Participants completed validated sleep assessments including the Insomnia Severity Index questionnaire, International Restless Legs Syndrome Study Group questionnaire, and in-home, wrist-worn overnight oximetry. They also completed health-related quality of life questionnaires including 36-item Short Form (SF-36) and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep questionnaires., Results: We enrolled 357 PWH (246 >50 years of age; 111 between 18 and 50 years) and 126 HIV-negative controls >50 years of age. Among PWH, criteria were met by 21% for insomnia, 13% for RLS, and 6% for SA. Compared with HIV-negative controls, PWH had a higher risk of insomnia (adjusted odds ratio, 5.3; 95% confidence interval, 2.2-12.9) but not RLS or SA. Compared with PWH without insomnia, those with insomnia reported significantly worse scores on all SF-36 and PROMIS components; fewer than 30% reported previous diagnosis or treatment for insomnia., Conclusions: Insomnia was more common in PWH, associated with worse health-related quality of life, and frequently undiagnosed. Further research should focus on the pathogenesis of insomnia in PWH and the development of effective screening and intervention strategies for this unique population., (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.)
- Published
- 2020
- Full Text
- View/download PDF
46. Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors.
- Author
-
De Francesco D, Sabin CA, Reiss P, and Kootstra NA
- Subjects
- Aged, Antiretroviral Therapy, Highly Active methods, Biomarkers blood, Blood Donors, Cohort Studies, Female, Humans, Inflammation immunology, Life Style, Male, Middle Aged, Aging immunology, CD4-Positive T-Lymphocytes immunology, HIV Infections immunology, Monocytes immunology
- Abstract
Motivation: People with HIV on successful antiretroviral therapy show signs of premature aging and are reported to have higher rates of age-associated comorbidities. HIV-associated immune dysfunction and inflammation have been suggested to contribute to this age advancement and increased risk of comorbidities., Method: Partial least squares regression (PLSR) was used to explore associations between biological age advancement and immunological changes in the T cell and monocyte compartment in people with HIV (n=40), comparable HIV-negative individuals (n=40) participating in the Comorbidity in Relation to AIDS (COBRA) cohort, and blood donors (n=35)., Results: We observed that age advancement in all three groups combined was associated with a monocyte immune phenotypic profile related to inflammation and a T cell immune phenotypic associated with immune senescence and chronic antigen exposure. Interestingly, a unique monocyte and T cell immune phenotypic profile predictive for age advancement was found within each group. An inflammatory monocyte immune phenotypic profile associated with age advancement in HIV-negative individuals, while the monocyte profile in blood donors and people with HIV was more reflective of loss of function. The T cell immune phenotypic profile in blood donors was related to loss of T cell function, whereas the same set of markers were related to chronic antigen stimulation and immune senescence in HIV-negative individuals. In people with HIV, age advancement was related to changes in the CD4
+ T cell compartment and more reflective of immune recovery after cART treatment., Impact: The identified monocyte and T cell immune phenotypic profiles that were associated with age advancement, were strongly related to inflammation, chronic antigen exposure and immune senescence. While the monocyte and T cell immune phenotypic profile within the HIV-negative individuals reflected those observed in the combined three groups, a distinct profile related to immune dysfunction, was observed within blood donors and people with HIV. These data suggest that varying exposures to lifestyle and infection-related factors may be associated with specific changes in the innate and adaptive immune system, that all contribute to age advancement., (Copyright © 2020 De Francesco, Sabin, Reiss and Kootstra.)- Published
- 2020
- Full Text
- View/download PDF
47. Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes.
- Author
-
Winston A, De Francesco D, Post F, Boffito M, Vera J, Williams I, Anderson J, Mallon PWG, and Sabin CA
- Subjects
- Anti-Retroviral Agents therapeutic use, CD4 Lymphocyte Count, COVID-19, Cohort Studies, Comorbidity, Cross-Sectional Studies, Female, HIV Infections drug therapy, Humans, Ireland epidemiology, Male, Middle Aged, Pandemics, Severity of Illness Index, United Kingdom epidemiology, Coronavirus Infections epidemiology, HIV Infections epidemiology, Pneumonia, Viral epidemiology
- Abstract
Objective: To determine comorbidity indices in people with HIV (PWH) and lifestyle-similar HIV-negative controls., Design: Cross-sectional analysis of the Pharmacokinetic and clinical Observations in PeoPle over fiftY cohort study in the United Kingdom and Ireland., Methods: The Elixhauser Comorbidity Index (ECI), Charlson Comorbidity Index and the Comorbidity Burden Index were compared between older PWH and HIV-negative controls using the Mann-Whitney U test; the magnitude of the difference between groups was quantified using the r effect size., Results: The 699 PWH and 304 HIV-negative controls were predominantly male (87.5% vs. 64.0%), white (86.3% vs. 90.0%) and had median ages of 57 and 58 years, respectively. Among PWH, the median (interquartile range) CD4 T-cell count was 624 (475, 811) cells/μl; 98.7% were on antiretroviral therapy. The median (interquartile range) ECI was 0 (0, 8) and 0 (-3, 1), Charlson Comorbidity Index was 2 (1, 5) and 1 (0, 1) and Comorbidity Burden Index 8.6 (2.2, 16.8) and 5.9 (0.6, 10.8), respectively. While all three indices were significantly higher in PWH than in controls (P < 0.001 for each), the magnitude of the differences between the two groups were small to medium, with effect sizes (95% confidence interval) of 0.21 (0.16, 0.27), 0.38 (0.32, 0.42) and 0.18 (0.11, 0.23), respectively., Conclusion: These three comorbidity indices are higher in PWH compared with HIV-negative controls, although the magnitude of differences between groups were small. Differences in the ECI, reportedly associated with poorer coronavirus disease 2019 outcomes, were driven by more individuals with HIV being within the higher end of the range.
- Published
- 2020
- Full Text
- View/download PDF
48. Associations Between Widespread Pain and Sleep Quality in People With HIV.
- Author
-
Sabin CA, Harding R, Doyle N, Redline S, de Francesco D, Mallon PWG, Post FA, Boffito M, Sachikonye M, Geressu A, Winston A, and Kunisaki KM
- Subjects
- Actigraphy, Cohort Studies, Female, Humans, Male, Middle Aged, HIV Infections complications, HIV-1, Pain, Sleep Wake Disorders etiology
- Abstract
Background: We investigate the association of widespread pain with sleep quality among people with HIV and HIV-negative controls., Setting: UK-based cohort., Methods: Pain information was collected through a pain mannikin identifying affected body sites; pain was classified as widespread if pain was reported in ≥4 of 5 body regions and in ≥7 of 15 body sites, and as regional otherwise. Sleep was assessed a median of 3.2 years later through 7-night actigraphy and through self-reported assessments of sleep quality. Chi-squared tests, Kruskal-Wallis tests, and linear/logistic regression considered associations between pain extent and sleep quality., Results: Of the 414 participants, 74 (17.9%) reported widespread and 189 (45.7%) regional pain. Although there were few clear associations between actigraphy outcomes and pain extent, those with widespread and regional pain consistently reported poorer sleep quality on all self-reported measures than those with no pain. Median (interquartile range) insomnia severity index and Patient-reported Outcomes Measurement Information System (PROMIS) for sleep disturbance and sleep-related impairment scores were 12 (7-16), 55.3 (48.0-58.9), and 57.2 (48.9-61.3), respectively, for those with widespread pain, 8 (4-13), 51.2 (45.5-58.3), and 50.3 (43.6-56.1) for those with regional pain, and 5 (2-9), 47.9 (42.9-54.3), and 45.5 (41.4-50.3) for those with no pain (all P values 0.0001). Associations remained strong after adjustment for HIV status and other confounders, and were reduced but remained significant, after adjustment for depressive symptoms., Conclusions: Widespread pain was not associated with objective measures of sleep but was strongly associated with self-reported assessments of sleep quality in people with HIV.
- Published
- 2020
- Full Text
- View/download PDF
49. Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.
- Author
-
De Francesco D, Underwood J, Bagkeris E, Anderson J, Williams I, Vera JH, Post FA, Boffito M, Johnson M, Mallon PWG, Winston A, and Sabin CA
- Subjects
- Adolescent, Adult, Cardiovascular Diseases pathology, Communicable Diseases pathology, Comorbidity, Female, Humans, Male, Mental Disorders pathology, Metabolic Diseases pathology, Middle Aged, Risk Factors, Severity of Illness Index, Treatment Outcome, Young Adult, Cardiovascular Diseases epidemiology, Communicable Diseases epidemiology, HIV Infections complications, Mental Disorders epidemiology, Metabolic Diseases epidemiology
- Abstract
Aims: To assess associations of comorbidity patterns observed in people living with HIV (PLWH) with risk factors and health outcomes., Methods: Common patters of comorbidities in PLWH participating in the Pharmacokinetic and Clinical Observations in People Over Fifty study were determined using principal component analysis and a severity score for each pattern was derived. Associations between each pattern's severity score and risk factors were assessed using median regression. The independent associations of patterns' severity scores with self-reported physical and mental health (SF-36 summary scores) were assessed using linear regression, with functional impairment (Lawton IADL < 8) and hospitalization in last year using logistic regression and with number of general practitioner visits using Poisson regression., Results: A total of 1073 PLWH were analysed: 85.2% male, median (interquartile range) age 52 (47-59) years, 98% on therapy. Duration of HIV was associated with higher severity in 4/6 of patterns: cardiovascular diseases, mental health problems, metabolic disorders and chest/other infections (all P ≤ 0.001). Prior AIDS was associated with higher severity scores for the same patterns and for the pattern of cancers (P < 0.001). The pattern of cardiovascular diseases was associated with poorer physical health (P = 0.02), higher risk of functional impairment (P = 0.02) and hospitalization (P < 0.001) and with higher number of general practitioner visits (P < 0.001). Severity of mental health (all P < 0.001) and of chest/other infections patterns negatively affected all the five health outcomes., Conclusion: Common patterns of comorbidities seen in PLWH appear to have different risk factors and to differently affect health outcomes. These findings may assist the development of targeted intervention to prevent, treat and manage the increasingly prevalent multimorbidity in PLWH.
- Published
- 2019
- Full Text
- View/download PDF
50. The Interplay Between Age and Frailty in People Living With HIV: Results From an 11-Year Follow-up Observational Study.
- Author
-
Guaraldi G, De Francesco D, Milic J, Franconi I, Mussini C, Falutz J, and Cesari M
- Abstract
Between 2006 and 2017, frailty prevalence decreased in HIV-positive individuals aged 50 years but presented a 3-fold increase among those 75 years of age. This dynamic relationship, defined as the frailty compression ratio, represents the net result of gero-inducing and gero-protective competing forces, described in the cohort.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.